Method for treating and preventing alzheimer's disease
By using anti-Aβ primary fibrillary antibodies such as BAN2401, the problem that the existing technology cannot slow down the disease progression is solved by targeting early Alzheimer's disease patients, and the effect of significantly reducing clinical decline and changing amyloid protein status and delaying disease progression is achieved. .
Patent Information
- Application Number
- CN202411217698.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-07-16
- Filing Date
- 2019-07-23
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art cannot effectively cure or slow the progress of Alzheimer's disease (AD), and there is a lack of preventive methods, and current treatment can only improve symptoms but cannot change the course of the disease.
Using a composition containing a therapeutically effective amount of an anti-Aβ primary fibrillary antibody, in particular BAN2401, to early stage Alzheimer's disease patients, transforming amyloid positive to negative by reducing Aβ deposition and existing plaques in the brain, Methods to reduce brain amyloid levels and prevent Alzheimer's disease.
It significantly reduced the clinical decline in patients with Alzheimer's disease, changed amyloid positive to negative, reduced the level of brain amyloid, delayed disease progression, and showed unforeseen beneficial effects for ApoE4 carriers.
Smart Images

Figure BDA0005022036930000451 
Figure BDA0005022036930002261 
Figure BDA0005022036930002262
Abstract
Description
[0001] This application is a divisional application of Chinese invention patent application No. 201980062781.8 (PCT application number PCT / US2019 / 043067), whose application date is July 23, 2019 and whose invention name is “Methods for the treatment and prevention of Alzheimer’s disease”.
[0002] This application claims the benefit of priority to U.S. Provisional Application No. 62 / 702,659, filed on July 24, 2018; U.S. Provisional Application No. 62 / 749,614, filed on October 23, 2018; U.S. Provisional Application No. 62 / 824,162, filed on March 26, 2019; U.S. Provisional Application No. 62 / 846,902, filed on May 13, 2019; and U.S. Provisional Application No. 62 / 874,684, filed on July 16, 2019; the entirety of each of which is incorporated herein by reference.
[0003] Alzheimer's disease (AD) is a progressive, neurodegenerative disorder of unknown etiology and is the most common form of dementia in the elderly. In 2006, there were 26.6 million cases of AD worldwide (range: 11.4 million to 59.4 million) (Brookmeyer, R. et al., Forecasting the global burden of Alzheimer's Disease. Alzheimer Dement. 2007;3:186-91), and more than 5 million people in the United States are reported to have AD (Alzheimer's Association. Alzheimer's Association report. 2010 Alzheimer's disease facts and figures. Alzheimer Dement. 2010;6:158-94). By 2050, the worldwide prevalence of AD is projected to grow to 106.8 million (range: 47.2 million to 221.2 million), with an estimated prevalence of 11 to 16 million in the United States alone (Brookmeyer, supra, and Alzheimer's disease facts and figures 2010, supra).
[0004] The disease generally involves a general decline in cognitive function that progresses slowly and leaves patients in the terminal stage bedridden. AD patients typically survive only 3 to 10 years after symptom onset, although extremes of 2 and 20 years have been known. (Hebert, LE et al., Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003; 60: 1119-1122.) Despite the fact that deaths due to AD are greatly underestimated because death certificates rarely attribute the cause of death to AD, AD remains the seventh leading cause of death in the United States and the fifth leading cause of death in Americans over 65 years of age. (Alzheimer's Association. Alzheimer's Association report. 2010 Alzheimer's disease facts and figures. Alzheimer Dement. 2010;6:158-94.)
[0005] AD represents a heavy economic burden in industrialized countries, with significant impacts on healthcare systems and public coffers, as well as on patients and their families. In the United States alone, total costs were estimated at $172 billion in 2010, including $123 billion for Medicare and Medicaid.
[0006] As far as we know, there is no cure for AD and no method to slow the progression of the disease. Current therapeutic agents used to treat AD include symptomatic therapeutic agents, such as acetylcholinesterase inhibitors (AChEIs), such as donepezil; and N-methyl-D-aspartate (NMDA)-receptor antagonists, such as memantine. Although these agents can improve AD symptoms, such as cognitive decline and decline in daily living activities and behaviors, they have not been reported to change the progression of the disease. Therefore, there is still an unmet need for methods to treat the progression of AD and / or prevent AD.
[0007] In some embodiments, provided herein is a method of reducing clinical decline in a subject with early Alzheimer's disease, the method comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the subject is an ApoE4 carrier. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0008] In some embodiments, at least one anti-Aβ protofibril antibody (e.g., BAN2401) prevents Aβ deposition before plaques begin to form in the brain. In some embodiments, at least one anti-Aβ protofibril antibody (e.g., BAN2401) reduces protofibrils and existing plaques in the brain. In some embodiments, at least one anti-Aβ protofibril antibody (e.g., BAN2401) prevents Aβ deposition before plaques begin to form and reduces protofibrils and existing plaques in the brain.
[0009] In some embodiments, provided herein is a method for converting a subject with amyloid-positive early Alzheimer's disease to a subject with amyloid-negative early Alzheimer's disease, the method comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the subject is an ApoE4 carrier. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0010] In some embodiments, provided herein is a method for reducing brain amyloid levels in a subject with early Alzheimer's disease, the method comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the subject is an ApoE4 carrier. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0011] In some embodiments, provided herein is a method for preventing Alzheimer's disease in an ApoE4-positive subject. In some embodiments, the method comprises determining the subject's brain amyloid level prior to administration, and administering a therapeutically effective amount of at least one anti-Aβ protofibril antibody if the subject's brain amyloid level is above a first predetermined level. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0012] This application relates to the following items:
[0013] Item 1
[0014] A method of reducing clinical decline in a subject with early-stage Alzheimer's disease, the method comprising administering a composition comprising a therapeutically effective amount of at least one anti-A[beta] protofibril antibody.
[0015] Item 2
[0016] The method according to claim 1, wherein the at least one anti-Aβ protofibril antibody comprises three heavy chain complementary determining regions (HCDR1, HCDR2 and HCDR3) comprising the amino acid sequence of SEQ ID NO: 5 (HCDR1), SEQ ID NO: 6 (HCDR2) and SEQ ID NO: 7 (HCDR 3); and three light chain complementary determining regions (LCDR1, LCDR2 and LCDR3) comprising the amino acid sequence of SEQ ID NO: 8 (LCDR1), SEQ ID NO: 9 (LCDR2) and SEQ ID NO: 10 (LCDR3).
[0017] Item 3
[0018] The method according to item 1, wherein the subject having early-stage Alzheimer's disease has been diagnosed with mild cognitive impairment with an intermediate likelihood of Alzheimer's disease, and / or has been diagnosed with mild Alzheimer's disease dementia.
[0019] Item 4
[0020] The method according to any one of items 1 to 3, wherein the subject is ApoE4 positive.
[0021] Item 5
[0022] The method according to any one of items 1 to 4, wherein the at least one anti-Aβ protofibril antibody is BAN2401.
[0023] Item 6
[0024] The method according to item 5, wherein the composition comprises 5 mg / kg to 10 mg / kg BAN2401 relative to the subject's body weight.
[0025] Item 7
[0026] The method of claim 5, wherein the composition comprises 10 mg / kg BAN2401 relative to the subject's body weight.
[0027] Item 8
[0028] The method according to any one of items 1 to 7, wherein the composition is administered once every 2 weeks or once a month.
[0029] Item 9
[0030] The method according to any one of items 1 to 8, wherein the clinical decline is reduced by at least 45% relative to placebo as measured by ADCOMS after 6 months of administration of the composition.
[0031] Item 10
[0032] The method according to any one of items 1 to 9, wherein the clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS after 12 months of administration of the composition.
[0033] Item 11
[0034] The method according to any one of items 1 to 10, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 30% relative to placebo as measured by ADCOMS.
[0035] Item 12
[0036] The method according to any one of items 1 to 11, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 47% relative to placebo as measured by ADAS-Cog.
[0037] Item 13
[0038] The method according to any one of items 1 to 12, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 26% relative to placebo as determined by CDR-SB.
[0039] Item 14
[0040] The method of claim 11, wherein the subject with early Alzheimer's disease has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease, and wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 33% relative to placebo as measured by ADCOMS.
[0041] Item 15
[0042] The method of claim 11, wherein the subject with early Alzheimer's disease has been diagnosed with mild Alzheimer's dementia, and wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS.
[0043] Item 16
[0044] The method according to any one of items 9 to 15, wherein the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered once every two weeks or once monthly.
[0045] Item 17
[0046] The method according to item 16, wherein the at least one anti-Aβ protofibril antibody is BAN 2401.
[0047] Item 18
[0048] The method according to any one of items 9 to 17, wherein the subject is ApoE4 positive.
[0049] Item 19
[0050] The method of item 18, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 63% relative to placebo as measured by ADCOMS.
[0051] Item 20
[0052] The method of item 18, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 84% relative to placebo as measured by ADAS-Cog.
[0053] Item 21
[0054] The method of item 18, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 60% relative to placebo as determined by CDR-SB.
[0055] Item 22
[0056] The method according to any one of items 1 to 17, wherein the subject is ApoE4 negative.
[0057] Item 23
[0058] The method according to any one of items 1 to 22, wherein the administration causes the Aβ level in the cerebrospinal fluid to 1-42 , total tau, phosphorylated tau, and / or neurogranin levels were decreased.
[0059] Item 24
[0060] The method according to any one of items 1 to 23, wherein the administration slows the increase in neurociliary light chain levels of the cerebrospinal fluid.
[0061] Item 25
[0062] The method according to any one of items 1 to 24, wherein the subject is concurrently administered at least one Alzheimer's disease drug other than BAN2401.
[0063] Item 26
[0064] The method according to any one of items 1 to 24, wherein the subject is not concurrently administered at least one Alzheimer's disease drug other than BAN2401.
[0065] Item 27
[0066] A method of converting an amyloid-positive subject with early-stage Alzheimer's disease to amyloid-negative comprises administering a composition comprising a therapeutically effective amount of at least one anti-A[beta] protofibril antibody.
[0067] Item 28
[0068] The method according to claim 27, wherein the at least one anti-Aβ protofibril antibody comprises three heavy chain complementary determining regions (HCDR1, HCDR2 and HCDR3) comprising the amino acid sequence of SEQ ID NO: 5 (HCDR1), SEQ ID NO: 6 (HCDR2) and SEQ ID NO: 7 (HCDR 3); and three light chain complementary determining regions (LCDR1, LCDR2 and LCDR3) comprising the amino acid sequence of SEQ ID NO: 8 (LCDR1), SEQ ID NO: 9 (LCDR2) and SEQ ID NO: 10 (LCDR3).
[0069] Item 29
[0070] The method of item 27, wherein the subject having early-stage Alzheimer's disease has been diagnosed with mild cognitive impairment with an intermediate likelihood of Alzheimer's disease, and / or has been diagnosed with mild Alzheimer's disease dementia.
[0071] Item 30
[0072] The method according to any one of items 27 to 29, wherein the subject is ApoE4 positive.
[0073] Item 31
[0074] The method according to any one of items 27 to 30, wherein the at least one anti-Aβ protofibril antibody is BAN2401.
[0075] Item 32
[0076] The method according to any one of items 27 to 31, wherein the composition comprises 5 mg / kg to 10 mg / kg BAN2401 relative to the subject's body weight.
[0077] Item 33
[0078] The method of claim 32, wherein the composition comprises 10 mg / kg BAN2401 relative to the subject's body weight.
[0079] Item 34
[0080] The method according to any one of items 27 to 33, wherein the composition is administered once every 2 weeks or once a month.
[0081] Item 35
[0082] The method of any one of items 27 to 31, wherein administration of the composition renders 50% to 100% of subjects amyloid negative as determined by visual reading of amyloid PET images 6 months after administration of the composition.
[0083] Item 36
[0084] The method of any one of items 27 to 31, wherein administration of the composition renders at least 55% of subjects amyloid negative as determined by visual reading of amyloid PET images 12 months after administration of the composition.
[0085] Item 37
[0086] The method according to any one of items 27 to 31, wherein after 18 months of administration of the composition,
[0087] Administration of the composition renders at least 70% of the subjects amyloid negative as determined by visual reading of amyloid PET images.
[0088] Item 38
[0089] The method according to any one of items 35 to 37, wherein the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered once every two weeks or once monthly.
[0090] Item 39
[0091] The method according to any one of items 35 to 38, wherein the at least one anti-Aβ protofibril antibody is BAN2401.
[0092] Item 40
[0093] The method according to any one of items 35 to 39, wherein the subject is ApoE4 positive.
[0094] Item 41
[0095] The method according to any one of items 35 to 39, wherein the subject is ApoE4 negative.
[0096] Item 42
[0097] The method according to any one of items 35 to 41, wherein the administration causes the Aβ level in the cerebrospinal fluid to 1-42 , total tau, phosphorylated tau, and / or neurogranin levels were decreased.
[0098] Item 43
[0099] The method according to any one of items 35 to 42, wherein the administration slows the increase in neurociliary light chain levels of the cerebrospinal fluid.
[0100] Item 44
[0101] A method of reducing brain amyloid levels in a subject in need thereof, the method comprising administering a composition comprising a therapeutically effective amount of at least one anti-A[beta] protofibril antibody.
[0102] Item 45
[0103] The method according to claim 44, wherein the antibody comprises three heavy chain complementary determining regions (HCDR1, HCDR2 and HCDR3) comprising the amino acid sequence of SEQ ID NO: 5 (HCDR 1), SEQ ID NO: 6 (HCDR2) and SEQ ID NO: 7 (HCDR3); and three light chain complementary determining regions (LCDR1, LCDR2 and LCDR3) comprising the amino acid sequence of SEQ ID NO: 8 (LCDR1), SEQ ID NO: 9 (LCDR2) and SEQ ID NO: 10 (LCDR3).
[0104] Item 46
[0105] The method of item 44 or 45, wherein the subject has Alzheimer's disease, Down syndrome, chronic traumatic encephalopathy, cerebral amyloid angiopathy, Lewy body dementia, or another brain disease or condition having soluble and / or insoluble Aβ aggregates containing Aβ peptides.
[0106] Item 47
[0107] The method according to item 46, wherein the Alzheimer's disease is early Alzheimer's disease.
[0108] Item 48
[0109] The method of item 47, wherein the subject having early-stage Alzheimer's disease has been diagnosed with mild cognitive impairment with an intermediate likelihood of Alzheimer's disease, and / or has been diagnosed with mild Alzheimer's disease dementia.
[0110] Item 49
[0111] The method of any one of items 44 to 48, wherein the subject is ApoE4 positive.
[0112] Item 50
[0113] The method according to any one of items 44 to 49, wherein the at least one anti-Aβ protofibril antibody is BAN2401.
[0114] Item 51
[0115] The method of item 50, wherein the composition comprises 2.5 mg / kg to 10 mg / kg BAN2401 relative to the subject's body weight.
[0116] Item 52
[0117] The method of claim 51, wherein the composition comprises 10 mg / kg BAN2401 relative to the subject's body weight.
[0118] Item 53
[0119] The method according to any one of items 44 to 52, wherein the composition is administered once every 2 weeks or once a month.
[0120] Item 54
[0121] The method of any one of items 44 to 53, wherein after 12 months of administration of the composition, the subject's adjusted mean change from baseline in PET SUVr value decreases by at least -0.20.
[0122] Item 55
[0123] The method of any one of items 44 to 53, wherein after 18 months of administration of the composition, the subjects have a corrected mean decrease from baseline in PET SUVr values of at least -0.25.
[0124] Item 56
[0125] The method according to any one of items 44 to 55, wherein the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered once every two weeks or once monthly.
[0126] Item 57
[0127] The method according to any one of items 44 to 55, wherein the at least one anti-Aβ protofibril antibody is BAN2401.
[0128] Item 58
[0129] The method of any one of items 44 to 57, wherein the subject is ApoE4 positive.
[0130] Item 59
[0131] The method according to any one of items 44 to 53, wherein the subject is ApoE4 negative.
[0132] Item 60
[0133] The method according to any one of items 44 to 59, wherein the administration causes the Aβ level in the cerebrospinal fluid to 1-42, total tau, phosphorylated tau, and / or neurogranin levels were decreased.
[0134] Item 61
[0135] The method according to any one of items 44 to 60, wherein the administration slows the increase in neurociliary light chain levels of the cerebrospinal fluid.
[0136] Item 62
[0137] A method of preventing Alzheimer's disease in a subject, the method comprising:
[0138] measuring brain amyloid levels in the subject;
[0139] administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody if the subject's brain amyloid level is above a first predetermined level,
[0140] measuring the level of amyloid in the brain of the subject after administration,
[0141] administering the composition if the brain amyloid level is above the second predetermined level after administration, and monitoring the subject's brain amyloid level after administration until the subject's brain amyloid level is below the first predetermined level,
[0142] Optionally, at least one additional therapeutic agent suitable for maintaining a predetermined brain amyloid level is administered, the at least one additional therapeutic agent selected from a BACE inhibitor, a γ-secretase inhibitor, a γ-secretase modulator, an Aβ peptide production inhibitor other than the at least one anti-Aβ protofibril antibody, an agent that reduces Aβ peptide levels other than the at least one anti-Aβ protofibril antibody, and combinations thereof.
[0143] Item 63
[0144] The method according to item 62, wherein the determination of brain amyloid levels before and / or after administration further comprises determining Aβ in cerebrospinal fluid before administration. 1-42 , levels of total tau, phosphorylated tau, neurogranin, and / or neurociliary light chain.
[0145] Item 64
[0146] The method according to item 62 or 63, further comprising:
[0147] If Aβ is administered to the cerebrospinal fluid 1-42 The composition is administered if the level of tau, total tau, phosphorylated tau, neurogranin and / or neurociliary light chain is above a predetermined level.
[0148] Item 65
[0149] The method according to any one of items 62 to 64, wherein the at least one anti-Aβ protofibril antibody is BAN2401.
[0150] Item 66
[0151] The method of item 65, wherein the composition comprises 2.5 mg / kg to 10 mg / kg BAN2401 relative to the subject's body weight.
[0152] Item 67
[0153] The method of claim 66, wherein the composition comprises 10 mg / kg BAN2401 relative to the subject's body weight.
[0154] Item 68
[0155] The method of any one of items 62 to 67, wherein the composition is administered once every 2 weeks or once a month.
[0156] Item 69
[0157] The method according to any one of items 62 to 68, wherein brain amyloid levels after the administration are reduced relative to brain amyloid levels before the administration.
[0158] Item 70
[0159] The method of any one of items 62 to 69, wherein the administration is interrupted if the brain amyloid level is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or 100% relative to the brain amyloid level before the administration.
[0160] Item 71
[0161] The method according to any one of items 62 to 70, wherein brain amyloid levels are assessed by visual reading of amyloid PET images.
[0162] Item 72
[0163] The method according to any one of items 62 to 71, wherein the Aβ in the cerebrospinal fluid after the administration is 1-42 Levels relative to Aβ in cerebrospinal fluid before administration 1-42 The level is reduced.
[0164] Item 73
[0165] The method according to any one of items 62 to 72, wherein the total tau level in the cerebrospinal fluid after the administration is reduced relative to the total tau level in the cerebrospinal fluid before the administration.
[0166] Item 74
[0167] The method according to any one of items 62 to 73, wherein the level of phospho-tau in the cerebrospinal fluid after the administration is reduced relative to the level of phospho-tau in the cerebrospinal fluid before the administration.
[0168] Item 75
[0169] The method according to any one of items 62 to 74, wherein the neurogranin level in the cerebrospinal fluid after the administration is reduced relative to the neurogranin level in the cerebrospinal fluid before the administration.
[0170] Item 76
[0171] The method according to any one of items 62 to 75, wherein the rate of increase of the neurociliary light chain level in the cerebrospinal fluid after the administration is slow relative to the rate of increase of the cerebrospinal fluid level before the administration.
[0172] Item 77
[0173] Method according to any one of items 62 to 76, wherein optionally administered at least one additional therapeutic agent suitable for maintaining a predetermined brain amyloid level is a BACE inhibitor.
[0174] Item 78
[0175] The method according to item 77, wherein the BACE inhibitor is elenbid.
[0176] Item 79
[0177] The method of any one of items 62 to 78, wherein the subject is ApoE4 positive.
[0178] Item 80
[0179] A method of preventing Alzheimer's disease in a subject, the method comprising:
[0180] measuring brain amyloid levels in the subject;
[0181] administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody and a composition comprising a therapeutically effective amount of at least one therapeutic agent selected from the group consisting of a BACE inhibitor, a γ-secretase inhibitor, a γ-secretase modulator, an Aβ peptide production inhibitor other than the at least one anti-Aβ protofibril antibody, and an agent that reduces Aβ peptide levels other than the at least one anti-Aβ protofibril antibody, if the subject's brain amyloid level is above a first predetermined level,
[0182] measuring the level of amyloid in the brain of the subject after administration,
[0183] administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody and a composition comprising a therapeutically effective amount of at least one therapeutic agent selected from the group consisting of a BACE inhibitor, a γ-secretase inhibitor, a γ-secretase modulator, an Aβ peptide production inhibitor other than the at least one anti-Aβ protofibril antibody, and an agent that reduces Aβ peptide levels other than the at least one anti-Aβ protofibril antibody, if the brain amyloid level after administration is above a second predetermined level,
[0184] monitoring the subject's brain amyloid level after the administering until the subject's brain amyloid level is below a first predetermined level,
[0185] administering at least one additional therapeutic agent suitable for maintaining a predetermined brain amyloid level, the at least one additional therapeutic agent selected from the group consisting of a BACE inhibitor, a γ-secretase inhibitor, a γ-secretase modulator, an Aβ peptide production inhibitor other than the at least one anti-Aβ protofibril antibody, and an agent that reduces Aβ peptide levels other than the at least one anti-Aβ protofibril antibody.
[0186] Item 81
[0187] The method according to item 80, wherein the determination of brain amyloid levels before and / or after administration further comprises determining Aβ in cerebrospinal fluid before administration. 1-42 , levels of total tau, phosphorylated tau, neurogranin, and / or neurociliary light chain.
[0188] Item 82
[0189] The method according to item 80 or 81, further comprising:
[0190] If Aβ is administered to the cerebrospinal fluid 1-42 The composition is administered if the level of tau, total tau, phosphorylated tau, neurogranin and / or neurociliary light chain is above a predetermined level.
[0191] Item 83
[0192] The method according to any one of items 80 to 82, wherein the at least one anti-Aβ protofibril antibody is BAN2401.
[0193] Item 84
[0194] The method according to any one of items 80 to 83, wherein the at least one therapeutic agent is a BACE inhibitor.
[0195] Item 85
[0196] The method according to item 84, wherein the BACE inhibitor is elenbid.
[0197] Item 86
[0198] The method of item 80, wherein the composition comprises 2.5 mg / kg to 10 mg / kg BAN2401 relative to the subject's body weight.
[0199] Item 87
[0200] The method of claim 86, wherein the composition comprises 10 mg / kg BAN2401 relative to the subject's body weight.
[0201] Item 88
[0202] The method of any one of items 80 to 87, wherein the composition is administered once every 2 weeks or once a month.
[0203] Item 89
[0204] The method according to any one of items 80 to 88, wherein brain amyloid levels after the administration are reduced relative to brain amyloid levels before the administration.
[0205] Item 90
[0206] The method of any one of items 80 to 89, wherein the administration is interrupted if the brain amyloid level is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or 100% relative to the brain amyloid level before the administration.
[0207] Item 91
[0208] The method according to any one of items 80 to 90, wherein brain amyloid levels are assessed by visual reading of amyloid PET images.
[0209] Item 92
[0210] The method according to any one of items 80 to 91, wherein the Aβ in the cerebrospinal fluid after the administration is 1-42 Levels relative to Aβ in cerebrospinal fluid before administration 1-42 The level is reduced.
[0211] Item 93
[0212] The method according to any one of items 80 to 92, wherein the total tau level in the cerebrospinal fluid after the administration is reduced relative to the total tau level in the cerebrospinal fluid before the administration.
[0213] Item 94
[0214] The method according to any one of items 80 to 93, wherein the level of phospho-tau in the cerebrospinal fluid after the administration is reduced relative to the level of phospho-tau in the cerebrospinal fluid before the administration.
[0215] Item 95
[0216] The method according to any one of items 80 to 94, wherein the neurogranin level in the cerebrospinal fluid after the administration is reduced relative to the neurogranin level in the cerebrospinal fluid before the administration.
[0217] Item 96
[0218] The method according to any one of items 80 to 95, wherein the rate of increase of the neurociliary light chain level in the cerebrospinal fluid after the administration is slow relative to the rate of increase of the cerebrospinal fluid level before the administration.
[0219] Item 97
[0220] Method according to any one of items 80 to 96, wherein optionally administered at least one additional therapeutic agent suitable for maintaining a predetermined brain amyloid level is a BACE inhibitor.
[0221] Item 98
[0222] The method according to item 97, wherein the BACE inhibitor is elenbid.
[0223] Item 99
[0224] A method for treating a subject with early Alzheimer's disease, the method comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, wherein after 6 months of administration of the composition, the subject's clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS; after 12 months of administration of the composition, the subject's clinical decline is reduced by at least 30% relative to placebo as measured by ADCOMS; and / or after 18 months of administration of the composition, the subject's clinical decline is reduced by at least 25% relative to placebo as measured by ADCOMS.
[0225] Item 100
[0226] The method according to claim 99, wherein the at least one anti-Aβ protofibril antibody comprises three heavy chain complementary determining regions (HCDR1, HCDR2 and HCDR3), which comprise the amino acid sequence of SEQ ID NO: 5 (HCDR1), SEQ ID NO: 6 (HCDR2) and SEQ ID NO: 7 (HCDR 3); and three light chain complementary determining regions (LCDR1, LCDR2 and LCDR3) which comprise the amino acid sequence of SEQ ID NO: 8 (LCDR1), SEQ ID NO: 9 (LCDR2) and SEQ ID NO: 10 (LCDR3).
[0227] Item 101
[0228] The method of item 99 or 100, wherein the subject having early-stage Alzheimer's disease has been diagnosed with mild cognitive impairment with an intermediate likelihood of Alzheimer's disease, and / or has been diagnosed with mild Alzheimer's disease dementia.
[0229] Item 102
[0230] The method according to any one of items 99 to 101, wherein the subject is ApoE4 positive.
[0231] Item 103
[0232] The method according to any one of items 99 to 102, wherein the at least one anti-Aβ protofibril antibody is BAN2401.
[0233] Item 104
[0234] The method of item 103, wherein the composition comprises 5 mg / kg to 10 mg / kg BAN2401 relative to the subject's body weight.
[0235] Item 105
[0236] The method of claim 103, wherein the composition comprises 10 mg / kg BAN2401 relative to the subject's body weight.
[0237] Item 106
[0238] The method according to any one of items 99 to 105, wherein the composition is administered once every 2 weeks or once a month.
[0239] Item 107
[0240] The method according to any one of items 99 to 106, wherein the clinical decline is reduced by at least 45% relative to placebo as measured by ADCOMS after 6 months of administration of the composition.
[0241] Item 108
[0242] The method according to any one of items 99 to 106, wherein the clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS after 12 months of administration of the composition.
[0243] Item 109
[0244] The method according to any one of items 99 to 106, wherein the clinical decline is reduced by at least 30% relative to placebo as measured by ADCOMS after 18 months of administration of the composition.
[0245] Item 110
[0246] The method of any one of items 99 to 106, wherein the clinical decline is reduced by at least 47% relative to placebo as measured by ADAS-Cog after 18 months of administration of the composition.
[0247] Item 111
[0248] The method of any one of items 99 to 106, wherein the clinical decline is reduced by at least 26% relative to placebo as determined by CDR-SB after 18 months of administration of the composition.
[0249] Item 112
[0250] The method of claim 109, wherein the subject with early Alzheimer's disease has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease, and wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 33% relative to placebo as measured by ADCOMS.
[0251] Item 113
[0252] The method of item 109, wherein the subject with early Alzheimer's disease has been diagnosed with mild Alzheimer's dementia, and wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS.
[0253] Item 114
[0254] The method according to any one of items 107 to 109, wherein the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered once every two weeks or once monthly.
[0255] Item 115
[0256] The method according to item 114, wherein the at least one anti-Aβ protofibril antibody is BAN2401.
[0257] Item 116
[0258] The method of any one of items 99 to 115, wherein the subject is ApoE4 positive.
[0259] Item 117
[0260] The method of item 116, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 63% relative to placebo as measured by ADCOMS.
[0261] Item 118
[0262] The method of item 116, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 84% relative to placebo as measured by ADAS-Cog.
[0263] Item 119
[0264] The method of item 116, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 60% relative to placebo as determined by CDR-SB.
[0265] Item 120
[0266] The method of any one of items 99 to 114, wherein the subject is ApoE4 negative.
[0267] Item 121
[0268] The method according to any one of items 99 to 120, wherein the administration causes the Aβ level in the cerebrospinal fluid to 1-42 , total tau, phosphorylated tau, and / or neurogranin levels were decreased.
[0269] Item 122
[0270] The method according to any one of items 99 to 121, wherein the administration slows the increase in neurociliary light chain levels of the cerebrospinal fluid.
[0271] Item 123
[0272] The method of any one of items 99 to 122, wherein the subject is concurrently administered at least one Alzheimer's disease drug other than BAN2401.
[0273] Item 124
[0274] The method of any one of items 99 to 122, wherein the subject is not concurrently administered at least one Alzheimer's disease drug other than BAN2401.
[0275] Item 125
[0276] A method of treating a subject with early-stage Alzheimer's disease, the method comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, wherein the severity of at least one symptom associated with Alzheimer's disease is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% relative to the severity of the same symptom in the same subject before treatment.
[0277] Item 126
[0278] The method according to claim 125, wherein the at least one anti-Aβ protofibril antibody comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) comprising the amino acid sequence of SEQ ID NO: 5 (HCDR1), SEQ ID NO: 6 (HCDR2) and SEQ ID NO: 7 (HCDR 3); and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) comprising the amino acid sequence of SEQ ID NO: 8 (LCDR1), SEQ ID NO: 9 (LCDR2) and SEQ ID NO: 10 (LCDR3).
[0279] Item 127
[0280] The method of item 125 or 126, wherein the subject having early-stage Alzheimer's disease has been diagnosed with mild cognitive impairment with an intermediate likelihood of Alzheimer's disease, and / or has been diagnosed with mild Alzheimer's disease dementia.
[0281] Item 128
[0282] The method according to any one of items 125 to 127, wherein the subject is ApoE4 positive.
[0283] Item 129
[0284] The method according to any one of items 125 to 128, wherein the at least one anti-Aβ protofibril antibody is BAN2401.
[0285] Item 130
[0286] The method of item 129, wherein the composition comprises 5 mg / kg to 10 mg / kg BAN2401 relative to the subject's body weight.
[0287] Item 131
[0288] The method of claim 129, wherein the composition comprises 10 mg / kg BAN2401 relative to the subject's body weight.
[0289] Item 132
[0290] The method according to any one of items 125 to 131, wherein the composition is administered once every 2 weeks or once a month.
[0291] Item 133
[0292] The method of any one of items 125 to 132, wherein the at least one symptom associated with Alzheimer's disease is clinical decline, and wherein the clinical decline is reduced by at least 45% relative to placebo as measured by ADCOMS after 6 months of administration of the composition.
[0293] Item 134
[0294] The method of any one of items 125 to 132, wherein the at least one symptom associated with Alzheimer's disease is clinical decline, and wherein the clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS after 12 months of administration of the composition.
[0295] Item 135
[0296] The method of any one of items 125 to 132, wherein the at least one symptom associated with Alzheimer's disease is clinical decline, and wherein the clinical decline is reduced by at least 30% relative to placebo as measured by ADCOMS after 18 months of administration of the composition.
[0297] Item 136
[0298] The method of any one of items 125 to 132, wherein the clinical decline is reduced by at least 47% relative to placebo as measured by ADAS-Cog after 18 months of administration of the composition.
[0299] Item 137
[0300] The method of any one of items 125 to 132, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 26% relative to placebo as determined by CDR-SB.
[0301] Item 138
[0302] The method of claim 135, wherein the subject with early Alzheimer's disease has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease, and wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 33% relative to placebo as measured by ADCOMS.
[0303] Item 139
[0304] The method of item 135, wherein the subject with early Alzheimer's disease has been diagnosed with mild Alzheimer's dementia, and wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS.
[0305] Item 140
[0306] The method according to any one of items 125 to 139, wherein the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered once every two weeks or once monthly.
[0307] Item 141
[0308] The method according to item 140, wherein the at least one anti-Aβ protofibril antibody is BAN2401.
[0309] Item 142
[0310] The method of any one of items 125 to 141, wherein the subject is ApoE4 positive.
[0311] Item 143
[0312] The method of item 142, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 63% relative to placebo as measured by ADCOMS.
[0313] Item 144
[0314] The method of item 142, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 84% relative to placebo as measured by ADAS-Cog.
[0315] Item 145
[0316] The method of item 142, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 60% relative to placebo as determined by CDR-SB.
[0317] Item 146
[0318] The method according to any one of items 125 to 145, wherein the at least one symptom associated with Alzheimer's disease is selected from clinical decline and brain amyloid levels.
[0319] Item 147
[0320] The method according to any one of items 125 to 146, wherein the administration causes the Aβ level in the cerebrospinal fluid to 1-42, total tau, phosphorylated tau, and / or neurogranin levels were decreased.
[0321] Item 148
[0322] The method of any one of items 125 to 147, wherein the administration slows the increase in neurociliary light chain levels of the cerebrospinal fluid.
[0323] Item 149
[0324] The method of any one of items 125 to 148, wherein the subject is concurrently administered at least one Alzheimer's disease drug other than BAN2401.
[0325] Item 150
[0326] The method of any one of items 125 to 148, wherein the subject is not concurrently administered at least one Alzheimer's disease drug other than BAN2401.
[0327] Item 151
[0328] A method of treating a subject with early-stage Alzheimer's disease, the method comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, wherein the severity of at least one symptom associated with Alzheimer's disease is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% relative to the severity of the same symptom in a subject receiving a placebo.
[0329] Item 152
[0330] The method according to item 151, wherein the severity of at least one symptom associated with Alzheimer's disease is determined by ADCOMS, PET, MMSE, CDR-SB and / or ADAS-Cog.
[0331] Item 153
[0332] The method according to claim 151, wherein the at least one anti-Aβ protofibril antibody comprises three heavy chain complementary determining regions (HCDR1, HCDR2 and HCDR3), which comprise the amino acid sequence of SEQ ID NO: 5 (HCDR1), SEQ ID NO: 6 (HCDR2) and SEQ ID NO: 7 (HCDR 3); and three light chain complementary determining regions (LCDR1, LCDR2 and LCDR3) which comprise the amino acid sequence of SEQ ID NO: 8 (LCDR1), SEQ ID NO: 9 (LCDR2) and SEQ ID NO: 10 (LCDR3).
[0333] Item 154
[0334] The method of item 151, wherein the subject having early-stage Alzheimer's disease has been diagnosed with mild cognitive impairment with an intermediate likelihood of Alzheimer's disease, and / or has been diagnosed with mild Alzheimer's disease dementia.
[0335] Item 155
[0336] The method according to any one of items 151 to 154, wherein the subject is ApoE4 positive.
[0337] Item 156
[0338] The method according to any one of items 151 to 155, wherein the at least one anti-Aβ protofibril antibody is BAN2401.
[0339] Item 157
[0340] The method of item 156, wherein the composition comprises 5 mg / kg to 10 mg / kg BAN2401 relative to the subject's body weight.
[0341] Item 158
[0342] The method of claim 156, wherein the composition comprises 10 mg / kg BAN2401 relative to the subject's body weight.
[0343] Item 159
[0344] The method according to any one of items 151 to 158, wherein the composition is administered once every 2 weeks or once a month.
[0345] Item 160
[0346] The method according to any one of items 151 to 159, wherein the clinical decline is reduced by at least 45% relative to placebo as measured by ADCOMS after 6 months of administration of the composition.
[0347] Item 161
[0348] The method of any one of items 151 to 159, wherein the at least one symptom associated with Alzheimer's disease is clinical decline, and wherein clinical decline is reduced by at least 35% relative to placebo after 12 months of administration of the composition as measured by ADCOMS.
[0349] Item 162
[0350] The method of any one of items 151 to 159, wherein the at least one symptom associated with Alzheimer's disease is clinical decline, and wherein clinical decline is reduced by at least 30% relative to placebo after 18 months of administration of the composition as measured by ADCOMS.
[0351] Item 163
[0352] The method of any one of items 151 to 159, wherein the clinical decline is reduced by at least 47% relative to placebo as measured by ADAS-Cog after 18 months of administration of the composition.
[0353] Item 164
[0354] The method of any one of items 151 to 159, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 26% relative to placebo as determined by CDR-SB.
[0355] Item 165
[0356] The method of claim 162, wherein the subject with early Alzheimer's disease has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease, and wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 33% relative to placebo as measured by ADCOMS.
[0357] Item 166
[0358] The method of item 162, wherein the subject with early Alzheimer's disease has been diagnosed with mild Alzheimer's dementia, and wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS.
[0359] Item 167
[0360] The method according to any one of items 160 to 166, wherein the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered once every two weeks or once monthly.
[0361] Item 168
[0362] The method according to item 167, wherein the at least one anti-Aβ protofibril antibody is BAN2401.
[0363] Item 169
[0364] The method according to any one of items 160 to 167, wherein the subject is ApoE4 positive.
[0365] Item 170
[0366] The method of item 169, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 63% relative to placebo as measured by ADCOMS.
[0367] Item 171
[0368] The method of item 169, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 84% relative to placebo as measured by ADAS-Cog.
[0369] Item 172
[0370] The method of item 169, wherein after 18 months of administration of the composition, the clinical decline is reduced by at least 60% relative to placebo as determined by CDR-SB.
[0371] Item 173
[0372] The method according to any one of items 151 to 169, wherein the at least one symptom associated with Alzheimer's disease is selected from clinical decline and brain amyloid levels.
[0373] Item 174
[0374] The method according to any one of items 151 to 173, wherein the administration causes the Aβ level in the cerebrospinal fluid to 1-42 , total tau, phosphorylated tau, and / or neurogranin levels were decreased.
[0375] Item 175
[0376] The method according to any one of items 151 to 173, wherein the administration slows the increase in neurociliary light chain levels of the cerebrospinal fluid.
[0377] Item 176
[0378] The method of any one of items 151 to 173, wherein the subject is concurrently administered at least one Alzheimer's disease drug other than BAN2401.
[0379] Item 177
[0380] The method of any one of items 151 to 173, wherein the subject is not concurrently administered at least one Alzheimer's disease drug other than BAN2401.
[0381] Item 178
[0382] The method of any one of items 80 to 99, wherein the subject is ApoE4 positive.
[0383] Item 179
[0384] The method of any one of items 27, 62 to 78, 80 to 98, 125 or 151, wherein the subject is ApoE4 negative. BRIEF DESCRIPTION OF THE DRAWINGS
[0385] Figure 1 Slowing of cognitive decline over 18 months relative to placebo as measured by ADCOMS was shown for BAN2401 doses of 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks.
[0386] Figure 2 Slowing of cognitive decline relative to placebo over 18 months as measured by ADCOMS is shown for monthly doses of 10 mg / kg BAN2401 and biweekly doses of 10 mg / kg BAN2401.
[0387] Figure 3 In subjects with mild cognitive impairment due to moderately likely Alzheimer's disease dementia, a dose of 10 mg / kg BAN2401 monthly and 10 mg / kg BAN2401 biweekly was shown to slow cognitive decline relative to placebo over 18 months as measured by ADCOMS.
[0388] Figure 4 In subjects with mild Alzheimer's disease dementia, a slowing of cognitive decline over 18 months relative to placebo was shown for monthly doses of 10 mg / kg BAN2401 and biweekly doses of 10 mg / kg BAN2401.
[0389] Figure 5 In ApoE4-positive subjects, a slowing of cognitive decline over 18 months relative to placebo was shown for monthly doses of 10 mg / kg BAN2401 and biweekly doses of 10 mg / kg BAN2401.
[0390] Figure 6 In ApoE4-negative subjects, a slowing of cognitive decline over 18 months relative to placebo was shown for monthly doses of 10 mg / kg BAN2401 and biweekly doses of 10 mg / kg BAN2401.
[0391] Figure 7Slowing of cognitive decline as measured by ADAS-cog over 18 months relative to placebo was shown for BAN2401 doses of 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks.
[0392] Figure 8 Slowing of cognitive decline relative to placebo over 18 months as measured by ADAS-cog was shown for monthly doses of 10 mg / kg BAN2401 and biweekly doses of 10 mg / kg BAN2401.
[0393] Figure 9 Slowing of cognitive decline relative to placebo over 18 months as determined by CDR-SB was shown for BAN2401 doses of 2.5 mg / kg biweekly, 5 mg / kg monthly, 5 mg / kg biweekly, 10 mg / kg monthly, and 10 mg / kg biweekly.
[0394] Figure 10 Slowing of cognitive decline relative to placebo over 18 months as measured by CDR-SB is shown for monthly doses of 10 mg / kg BAN2401 and biweekly doses of 10 mg / kg BAN2401.
[0395] Figure 11 Reductions in brain amyloid as measured by PET over 18 months are shown for BAN2401 doses of 2.5 mg / kg biweekly, 5 mg / kg monthly, 5 mg / kg biweekly, 10 mg / kg monthly, and 10 mg / kg biweekly, as measured by PET, for whole cortex mean versus whole cerebellum reference.
[0396] Figure 12 Reductions in brain amyloid as measured by imaging with a radiotracer that binds to brain Aβ amyloid and visualized by PET were shown for doses of BAN2401 at 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks over 18 months.
[0397] Figure 13 Shown are the conversions of amyloid-positive subjects to amyloid-negative subjects after 12 and 18 months of treatment as determined by visual readout for BAN2401 doses of 2.5 mg / kg biweekly, 5 mg / kg monthly, 5 mg / kg biweekly, 10 mg / kg monthly, and 10 mg / kg biweekly.
[0398] Figure 14showed that BAN2401 doses of 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks reduced cerebrospinal fluid Aβ over 18 months. 1-42 Changes in levels.
[0399] Figure 15 Shown are changes in cerebrospinal fluid total tau levels over 18 months for monthly and biweekly doses of 10 mg / kg BAN2401.
[0400] Figure 16 In ApoE4-positive subjects, doses of BAN2401 at 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks were shown to slow cognitive decline relative to placebo over 18 months as measured by ADCOMS.
[0401] Figure 17 In ApoE4-positive subjects with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease, a dose of 10 mg / kg BAN2401 monthly and 10 mg / kg BAN2401 biweekly was shown to slow cognitive decline relative to placebo over 18 months as measured by ADCOMS.
[0402] Figure 18 In ApoE4-positive subjects with mild Alzheimer's disease dementia, a slowing of cognitive decline over 18 months relative to placebo was shown for monthly doses of 10 mg / kg BAN2401 and biweekly doses of 10 mg / kg BAN2401.
[0403] Figure 19 In ApoE4-positive subjects, doses of BAN2401 at 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks were shown to slow cognitive decline relative to placebo over 18 months, as measured by ADAS-cog.
[0404] Figure 20 In ApoE4-positive subjects, monthly 10 mg / kg and biweekly 10 mg / kg doses of BAN2401 were shown to slow cognitive decline relative to placebo over 18 months as measured by ADAS-cog.
[0405] Figure 21In ApoE4-positive subjects with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease, a dose of 10 mg / kg BAN2401 monthly and 10 mg / kg BAN2401 biweekly was shown to slow cognitive decline relative to placebo over 18 months as measured by the ADAS-cog.
[0406] Figure 22 In ApoE4-positive subjects with mild Alzheimer's disease dementia, a dose of 10 mg / kg BAN2401 monthly and 10 mg / kg BAN2401 biweekly was shown to slow cognitive decline relative to placebo over 18 months as measured by ADAS-cog.
[0407] Figure 23 In ApoE4-positive subjects, a reduction in cognitive decline over 18 months was shown for BAN2401 doses of 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks relative to placebo as determined by CDR-SB.
[0408] Figure 24 In ApoE4-positive subjects, monthly 10 mg / kg and biweekly 10 mg / kg doses of BAN2401 were shown to slow cognitive decline relative to placebo over 18 months as measured by CDR-SB.
[0409] Figure 25 In ApoE4-positive subjects with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease, a dose of 10 mg / kg BAN2401 monthly and 10 mg / kg BAN2401 biweekly was shown to slow cognitive decline relative to placebo over 18 months as measured by CDR-SB.
[0410] Figure 26 In ApoE4-positive subjects with mild Alzheimer's disease dementia, a slowing of cognitive decline relative to placebo over 18 months was shown for monthly doses of 10 mg / kg BAN2401 and biweekly doses of 10 mg / kg BAN2401.
[0411] Figure 27In ApoE4-positive subjects, doses of BAN2401 at 2.5 mg / kg biweekly, 5 mg / kg monthly, 5 mg / kg biweekly, 10 mg / kg monthly, and 10 mg / kg biweekly were shown to reduce brain amyloid as measured by visual reading of amyloid PET images over 18 months, as measured by global cortical mean versus whole cerebellum reference.
[0412] Figure 28 In ApoE4-positive subjects, doses of BAN2401 at 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks were shown to reduce brain amyloid over 18 months as measured by imaging with a radiotracer that binds to brain Aβ amyloid and visualized by PET.
[0413] Figure 29 Shown is the conversion of amyloid-positive, ApoE4-positive subjects to amyloid-negative, ApoE4-positive subjects after 12 and 18 months of treatment.
[0414] Figure 30 In ApoE4-positive subjects, BAN2401 doses of 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks reduced cerebrospinal fluid Aβ levels over 18 months. 1-42 Changes in levels.
[0415] Figure 31 Shown are changes in cerebrospinal fluid total tau levels over 18 months in ApoE4-positive subjects in response to monthly dosing of 10 mg / kg BAN2401 and biweekly dosing of 10 mg / kg BAN2401.
[0416] Figure 32 In ApoE4-negative subjects, doses of BAN2401 at 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks were shown to slow cognitive decline relative to placebo over 18 months as measured by ADCOMS.
[0417] Figure 33 In ApoE4-negative subjects with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease, a dose of 10 mg / kg BAN2401 monthly and 10 mg / kg BAN2401 biweekly was shown to slow cognitive decline relative to placebo over 18 months as measured by ADCOMS.
[0418] Figure 34 In ApoE4-negative subjects with mild Alzheimer's disease dementia, a slowing of cognitive decline over 18 months relative to placebo was shown for monthly doses of 10 mg / kg BAN2401 and biweekly doses of 10 mg / kg BAN2401.
[0419] Figure 35 In ApoE4-negative subjects, doses of BAN2401 at 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks were shown to slow cognitive decline relative to placebo over 18 months, as measured by ADAS-cog.
[0420] Figure 36 In ApoE4-negative subjects, monthly 10 mg / kg and biweekly 10 mg / kg doses of BAN2401 were shown to slow cognitive decline relative to placebo over 18 months as measured by ADAS-cog.
[0421] Figure 37 In ApoE4-negative subjects with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease, a dose of 10 mg / kg BAN2401 monthly and 10 mg / kg BAN2401 biweekly was shown to slow cognitive decline relative to placebo over 18 months as measured by ADAS-cog.
[0422] Figure 38 In ApoE4-negative subjects with mild Alzheimer's disease dementia, a dose of 10 mg / kg BAN2401 monthly and 10 mg / kg BAN2401 biweekly was shown to slow cognitive decline relative to placebo over 18 months as measured by ADAS-cog.
[0423] Figure 39 In ApoE4-negative subjects, a reduction in cognitive decline over 18 months was shown for BAN2401 at doses of 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks relative to placebo as determined by CDR-SB.
[0424] Figure 40 In ApoE4-negative subjects, monthly 10 mg / kg and biweekly 10 mg / kg doses of BAN2401 were shown to slow cognitive decline relative to placebo over 18 months as determined by CDR-SB.
[0425] Figure 41 In ApoE4-negative subjects with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease, a slowing of cognitive decline relative to placebo over 18 months was demonstrated for doses of 10 mg / kg BAN2401 monthly and 10 mg / kg BAN2401 biweekly, as measured by CDR-SB.
[0426] Figure 42 In ApoE4-negative subjects with mild Alzheimer's disease dementia, a dose of 10 mg / kg monthly and 10 mg / kg biweekly of BAN2401 was shown to slow cognitive decline relative to placebo over 18 months as measured by CDR-SB.
[0427] Figure 43 In ApoE4-negative subjects, doses of BAN2401 at 2.5 mg / kg biweekly, 5 mg / kg monthly, 5 mg / kg biweekly, 10 mg / kg monthly, and 10 mg / kg biweekly were shown to reduce brain amyloid as measured by visual reading of amyloid PET images over 18 months as a whole cortex mean versus a whole cerebellum reference.
[0428] Figure 44 In ApoE4-negative subjects, doses of BAN2401 at 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks were shown to reduce brain amyloid over 18 months as measured by imaging with a radiotracer that binds to brain Aβ amyloid and visualized by PET.
[0429] Figure 45 Shown is the conversion of amyloid-positive, ApoE4-negative subjects to amyloid-negative, ApoE4-negative subjects after 12 and 18 months of treatment.
[0430] Figure 46 In ApoE4-negative subjects, BAN2401 doses of 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks reduced cerebrospinal fluid Aβ levels over 18 months. 1-42 Changes in levels.
[0431] Figure 47 Shown are changes in cerebrospinal fluid total tau levels over 18 months in ApoE4-negative subjects for a 10 mg / kg monthly dose and a 10 mg / kg biweekly dose.
[0432] Figure 48 Slowing of cognitive decline at 18 months relative to placebo as measured by ADCOMS, ADAS-Cog, or CDR-SB is shown in ApoE4-positive and ApoE4-negative subjects, and for all subjects regardless of genotype, for a dose of 10 mg / kg BAN2401 every two weeks.
[0433] Figure 49 To show a reduction in cognitive decline relative to placebo at 18 months for a dose of 10 mg / kg BAN2401 every two weeks in subjects with mild cognitive impairment due to intermediate likelihood of Alzheimer's dementia or mild Alzheimer's dementia, and for all subjects regardless of disease type or status, as measured by ADCOMS, ADAS-Cog, or CDR-SB.
[0434] Figure 50 To show a reduction in cognitive decline at 18 months relative to placebo for a dose of 10 mg / kg BAN2401 every two weeks as measured by ADCOMS, ADAS-Cog, or CDR-SB in subjects concomitantly taking at least one Alzheimer's disease medication other than BAN2401 and in subjects not concomitantly taking at least one Alzheimer's disease medication other than BAN2401, and for all subjects regardless of whether the subjects were concomitantly taking at least one Alzheimer's disease medication other than BAN2401.
[0435] Figure 51 Shown is the clearance of brain amyloid relative to placebo at 18 months for a dose of 10 mg / kg BAN2401 every two weeks, as measured by PET, in the following subpopulations: ApoE4-positive subjects; ApoE4-negative subjects; subjects with mild cognitive impairment due to intermediate-probable Alzheimer's disease dementia; subjects with mild Alzheimer's disease dementia; subjects concomitantly taking at least one Alzheimer's disease medication other than BAN2401; and subjects not concomitantly taking at least one Alzheimer's disease medication other than BAN2401.
[0436] Figure 52 A reduction in cognitive decline at 18 months relative to placebo, as measured by ADCOMS, was shown for a dose of 10 mg / kg BAN2401 every two weeks in the following subpopulations: ApoE4-positive subjects; ApoE4-negative subjects; subjects with mild cognitive impairment due to intermediate-probable Alzheimer's dementia; subjects with mild Alzheimer's dementia; subjects concomitantly taking at least one Alzheimer's medication other than BAN2401; and subjects not concomitantly taking at least one Alzheimer's medication other than BAN2401.
[0437] Figure 53 Shown are changes in cerebrospinal fluid neurogranin levels relative to placebo at 18 months as means for subjects receiving either 10 mg / kg BAN2401 every two weeks or 10 mg / kg BAN2401 monthly.
[0438] Figure 54 Shown are changes in cerebrospinal fluid phospho-tau levels relative to placebo at 18 months as means for subjects receiving either 10 mg / kg BAN2401 every two weeks or 10 mg / kg BAN2401 monthly.
[0439] Figure 55 Shown are changes in cerebrospinal fluid neurociliary light chain levels relative to placebo at 18 months as means for subjects receiving either 10 mg / kg BAN2401 every two weeks or 10 mg / kg BAN2401 monthly.
[0440] Figure 56 Slowing of cognitive decline at 18 months relative to placebo as measured by ADCOMS and PET is shown for doses of 10 mg / kg BAN2401 every two weeks or 10 mg / kg BAN2401 monthly.
[0441] Figure 57 A correlation was shown between reductions in brain amyloid and increases in clinical improvement as measured by ADCOMS, ADAS-Cog, and CDR-SB.
[0442] Figure 58 ApoE4-positive and ApoE4-negative subjects who were not administered BAN2401 were shown to experience similar rates of disease progression.
[0443] Figure 59 Shown are the effects of multiple factors on disease progression as measured by ADCOMS.
[0444] Figure 60 Shown are the changes in BAN2401 concentrations over time following administration of monthly and biweekly doses of 10 mg / kg BAN2401.
[0445] Figure 61 Depicts that BAN2401 preferentially binds to larger Aβ protofibrils compared to monomers, dimers, and oligomers of Aβ peptide.
[0446] Figure 62 The proportion of subjects experiencing an ARIA-E event is shown as a function of the maximum plasma concentration of BAN2401.
[0447] Figure 63 Administration of BAN2401 was shown to significantly reduce amyloid PET values at all doses.
[0448] Figure 64 Shows an overview of study designs for early intervention and prevention of Alzheimer's disease.
[0449] Figure 65 Shown are the adjusted mean changes from baseline (least squares means, "LSM") in cerebrospinal fluid phospho-tau levels relative to placebo over 18 months for BAN2401 doses of 2.5 mg / kg biweekly, 5 mg / kg monthly, 5 mg / kg biweekly, 10 mg / kg monthly, and 10 mg / kg biweekly.
[0450] Figure 66 Shown are the adjusted mean changes (LSM) from baseline in cerebrospinal fluid neurogranin levels relative to placebo over 18 months for BAN2401 doses of 2.5 mg / kg biweekly, 5 mg / kg monthly, 5 mg / kg biweekly, 10 mg / kg monthly, and 10 mg / kg biweekly.
[0451] Figure 67 Shown are the adjusted mean changes (LSM) from baseline in cerebrospinal fluid neurociliary light chain levels relative to placebo over 18 months for BAN2401 doses of 2.5 mg / kg biweekly, 5 mg / kg monthly, 5 mg / kg biweekly, 10 mg / kg monthly, and 10 mg / kg biweekly.
[0452] Figure 68 Shown are the adjusted mean changes from baseline (LSM) in cerebrospinal fluid phospho-tau levels for the combined 10 mg / kg doses of BAN2401 (10 mg / kg monthly and 10 mg / kg every two weeks) relative to placebo over 18 months.
[0453] Figure 69 Shown are the adjusted mean changes (LSM) from baseline in cerebrospinal fluid phospho-tau levels for the combined 10 mg / kg doses of BAN2401 (10 mg / kg monthly and 10 mg / kg every two weeks) relative to placebo over 18 months in ApoE4-positive subjects.
[0454] Figure 70 Shown are the adjusted mean changes (LSM) from baseline in cerebrospinal fluid phospho-tau levels for the combined 10 mg / kg doses of BAN2401 (10 mg / kg monthly and 10 mg / kg every two weeks) relative to placebo over 18 months in ApoE4-negative subjects.
[0455] Figure 71 Shown are the adjusted mean changes from baseline (LSM) in cerebrospinal fluid neurogranin levels for the combined 10 mg / kg doses of BAN2401 (10 mg / kg monthly and 10 mg / kg biweekly) relative to placebo over 18 months.
[0456] Figure 72 Shown are the adjusted mean changes (LSM) from baseline in cerebrospinal fluid neurogranin levels for the combined 10 mg / kg doses of BAN2401 (10 mg / kg monthly and 10 mg / kg every two weeks) relative to placebo over 18 months in ApoE4-positive subjects.
[0457] Figure 73 Shown are the adjusted mean changes (LSM) from baseline in cerebrospinal fluid neurogranin levels for the combined 10 mg / kg doses of BAN2401 (10 mg / kg monthly and 10 mg / kg every two weeks) relative to placebo over 18 months in ApoE4-negative subjects.
[0458] Figure 74 Shown are the adjusted mean changes (LSM) from baseline in cerebrospinal fluid neurociliary light chain levels for the combined 10 mg / kg doses of BAN2401 (10 mg / kg monthly and 10 mg / kg every two weeks) relative to placebo over 18 months.
[0459] Figure 75 Shown are the adjusted mean changes (LSM) from baseline in cerebrospinal fluid neurociliary light chain levels for the combined 10 mg / kg doses of BAN2401 (10 mg / kg monthly and 10 mg / kg every two weeks) relative to placebo over 18 months in ApoE4-positive subjects.
[0460] Figure 76 Shown are the adjusted mean changes (LSM) from baseline in cerebrospinal fluid neurociliary light chain levels for the combined 10 mg / kg doses of BAN2401 (10 mg / kg monthly and 10 mg / kg every two weeks) relative to placebo over 18 months in ApoE4-negative subjects.
[0461] Figure 77 Correlations between changes from baseline in PET standardized uptake value ratios (normalized to whole cerebellar masking) and cognitive outcomes at 12 and 18 months were shown for placebo and BAN2401 doses of 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks.
[0462] Figure 78 Correlations between changes from baseline in PET standardized uptake value ratios (normalized to whole cerebellar shielding) and cognitive outcomes at 12 and 18 months were shown for placebo and BAN2401 doses of 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks.
[0463] Figure 79 Correlations between changes from baseline in PET standardized uptake value ratios (normalized to whole cerebellar masking) and cognitive outcomes at 12 and 18 months were shown for placebo and BAN2401 doses of 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks.
[0464] Figure 80 Correlations between changes from baseline in PET standardized uptake value ratio (normalized to subcortical white matter) and cognitive outcomes at 12 and 18 months were shown for placebo and BAN2401 doses of 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks.
[0465] Figure 81 Correlations between changes from baseline in PET standardized uptake value ratio (normalized to subcortical white matter) and cognitive outcomes at 12 and 18 months were shown for placebo and BAN2401 doses of 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks.
[0466] Figure 82 Correlations between changes from baseline in PET standardized uptake value ratio (normalized to subcortical white matter) and cognitive outcomes at 12 and 18 months were shown for placebo and BAN2401 doses of 2.5 mg / kg every two weeks, 5 mg / kg monthly, 5 mg / kg every two weeks, 10 mg / kg monthly, and 10 mg / kg every two weeks.
[0467] "Amyloid hypothesis"
[0468] The "amyloid hypothesis" proposes that amyloid β (Aβ) peptides play a central role in the pathogenesis of AD. Specifically, it is hypothesized that neurodegeneration in AD can be caused by the deposition of Aβ plaques in brain tissue, which is attributed to an imbalance between Aβ production and Aβ clearance, resulting in the formation of neurofibrillary tangles containing tau protein. Aβ peptides generally exist in a dynamic continuous conformation, such that species tend to develop from monomeric Aβ into soluble Aβ aggregates, which include a range of low molecular weight oligomers to higher molecular weight protofibrils, and finally develop into insoluble protofibrils (plaques). With the intention of reducing the amount of insoluble Aβ fibrils deposited in the brain, a variety of immunotherapies have been developed. However, a simple correlation between the amount of insoluble amyloid plaques and the progressive accumulation and the clinical course of AD has not yet been determined. Although therapeutic strategies continue to focus on removing insoluble amyloid plaques, an additional treatment method may include reducing toxic Aβ aggregates, such as protofibrils, which can contribute to the neuronal degeneration characteristics of AD. (See, e.g., Dodott, J.-C. and May, P., “Overview onrodent models of Alzheimer's disease.” Curr. Protocols Neurosci. 2005;9.22-1-9.22-6; Englund, H. et al., “Sensitive ELISA detection of amyloid-β protofibrils in biological samples.” J. Neurochem. 2007;103:334-45; and Gotz, J. et al., “Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior, and therapy. Mol. Psychiat. 2004;9:664-83.
[0469] It is hypothesized that BAN2401 and other anti-Aβ protofibril antibodies can be used to slow the progression of AD in subjects in the early stages of the disease, when amyloid has already deposited in the brain, but the downstream neurodegenerative cascade believed to be triggered by amyloid deposition is still relatively early in its course (i.e., limited brain tissue damage has occurred and the associated clinical deficits are at a minimal level). As disclosed herein, using BAN2401 as an exemplary anti-Aβ protofibril antibody, the inventors have discovered a novel method for reducing brain amyloid levels in amyloid-positive early-stage AD subjects. Also disclosed herein is a novel method for converting amyloid-positive early-stage AD subjects to amyloid-negative, comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. Also disclosed herein is a method for reducing clinical decline in amyloid-positive early-stage AD subjects, comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. As will be discussed, unexpected beneficial results were achieved when the subject was ApoE4 positive.
[0470] Surprisingly and unforeseen, the present inventors have also discovered a method for preventing and / or delaying the onset of AD in a subject with early-stage AD, comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the subject is ApoE4 positive. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0471] definition
[0472] The following are definitions of terms used in this application.
[0473] As used herein, the singular terms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0474] As used herein, the phrase "and / or" means "either or both" of the elements so conjoined, i.e., elements that are present in conjunction in some cases and not in conjunction in other cases. Thus, as a non-limiting example, "A and / or B," when used in conjunction with open language such as "comprising," may, in some embodiments, refer to only A (optionally including elements other than B); in other embodiments, only B (optionally including elements other than A); in still other embodiments, both A and B (optionally including other elements); etc.
[0475] As used herein, "at least one" means one or more elements in a list of elements, but does not necessarily include at least one of every element specifically listed in the list of elements, and does not exclude any combination of elements in the list of elements. This definition also allows for the optional presence of elements other than the elements specifically identified in the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, "at least one A and B" (or equivalently "at least one A or B," or, equivalently "at least one A and / or B"), in one embodiment, may refer to at least one (optionally including more than one) A without B (and optionally including elements other than B); in another embodiment, to at least one (optionally including more than one) B without A (and optionally including elements other than A); in yet another embodiment, to at least one (optionally including more than one) A and at least one (optionally including more than one) B (and optionally including other elements); etc.
[0476] When a number is recited either alone or as part of a numerical range, it is understood that the value can vary by 10% above and below the stated value.
[0477] When a range of values is listed herein, it is intended that each value and subrange be encompassed within that range. For example, "2.5 mg / kg to 10 mg / kg" is intended to encompass, for example, 2.5 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 mg / kg, 4.5 mg / kg, 5 mg / kg, 5.5 mg / kg, 6 mg / kg, 6.5 mg / kg, 7 mg / kg, 7.5 mg / kg, 8 mg / kg, 8.5 mg / kg, 9 mg / kg, 9.5 mg / kg, 10 mg / kg, 2.5 mg / kg to 3 mg / kg, 2.5 mg / kg to 4.5 mg / kg, 3 mg / kg to 4.5 mg / kg, 4.5 mg / kg to 8 mg / kg, 2.5 mg / kg to 9 mg / kg, etc.
[0478] As used herein, "early AD" or "early Alzheimer's disease" is a continuum of AD severity ranging from mild cognitive impairment with an intermediate likelihood of AD to mild Alzheimer's dementia. Subjects with early AD include subjects with mild Alzheimer's dementia as defined herein and subjects with MCI with an intermediate likelihood of AD as defined herein. In some embodiments, subjects with early AD have an MMSE of 22 to 30 and a total CDR range of 0.5 to 1.0.
[0479] As used herein, a subject with "mild Alzheimer's dementia" is one who meets the NIA-AA core clinical criteria for possible Alzheimer's dementia as set forth in McKhann, GM, et al., "The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." Alzheimer Dement. 2011;7:263-9. Also included herein are subjects with a CDR score of 0.5 to 1.0 and a Memory Box score of 0.5 or greater at Screening and Baseline.
[0480] As used herein, subjects with "MCI due to moderate likelihood of AD" are subjects identified as such according to the NIA-AA core clinical criteria (see McKhann, supra) for mild cognitive impairment due to moderate likelihood of Alzheimer's disease. For example, as measured by the ADCOMS Composite Clinical Score defined herein, symptomatic but not demented AD subjects with brain amyloid pathology have less heterogeneity than subjects with mild Alzheimer's disease dementia and are more similar in cognitive and functional decline. Also included are subjects with a CDR score of 0.5 and a memory box score of 0.5 or higher at screening and baseline. In addition, subjects with a history of subjective memory decline and gradual onset and slow progression within the last year prior to screening, as confirmed by an informant, are also included herein.
[0481] As used herein, "MMSE" refers to the Mini-Mental State Examination, a cognitive tool commonly used for screening purposes and also commonly measured longitudinally in AD clinical trials, which has a 30-point scale in which higher scores indicate lower degrees of impairment and lower scores indicate higher degrees of impairment. As used herein, the assessment measures seven items of time and place orientation, recording, recall, attention, language, and drawing. (Folstein, MF et al., "Mini-mental state. A practical method for grading the cognitive state of patients for the clinician." J. Psychiatr. Res. 1975; 12: 189-98.)
[0482] As used herein, "ADAS-cog" refers to the Alzheimer's Disease Assessment Scale-Cognitive. ADAS-cog is a cognitive scale commonly used in Alzheimer's disease trials, with a structural scale that assesses memory (word recall, delayed word recall, and word recognition), reasoning (following commands), language (naming, understanding), orientation, conceptual practice (putting a letter in an envelope), and construction practice (copying a geometric design). (Rosen, WG et al., "A new rating scale for Alzheimer's disease." Am. J. Psychiatry [American Journal of Psychiatry] 1984; 141: 1356-64.) Spoken language, language comprehension, word recall difficulties, the ability to remember test instructions, mazes, and digital crossouts are also obtained. The modified form used herein is scored on a scale of 0 to 90 points, with 0 indicating no barrier and 90 indicating the highest degree of barrier.
[0483] As used herein, "CDR-SB" refers to the clinical dementia rating-sum of boxes. The CDR is a clinical scale that describes five degrees of impairment in the performance of six functional categories, including memory, orientation, judgment and problem solving, group work, family and hobbies, and personal care. (Berg, L. et al., "Mildseniledementia of the Alzheimer type: 2. Longitudinal assessment." Ann. Neurol. 1988; 23: 477-84.) The degree of impairment obtained for each of the six functional categories is synthesized into a total grade of the dementia CDR score (ranging from 0 to 3). The sum of the box scores provides another measure of variation, where each category has a maximum possible score of 3 points, and the total score is the sum of the scores for each category, resulting in a total possible score of 0 to 18, with higher scores indicating a higher degree of impairment. The total score can be used as a clinical measure of the severity of dementia.
[0484] As used herein, "ADCOMS" refers to the Alzheimer's Disease Composite Score, a composite clinical score based on four ADAS-Cog items (delayed word recall, orientation, word recognition, and word retrieval difficulty), two MMSE items (time orientation and drawing), and all six CDR-SB items (personal care, group activities, family and hobbies, memory, orientation, and judgment and problem solving), as described in the Examples and in Wang, J. et al., "ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials." J. Neurol. Neurosurg. Psychiatry. 2016;87:993-999. ADCOMS was developed to be particularly sensitive to disease progression in the early stages of AD, i.e., during the prodromal and mild AD phases.
[0485] As used herein, "ApoE4-positive" subjects and "ApoE4 carriers" refer to subjects with the ε4 variant of the apolipoprotein gene. The ε4 variant is one of several major alleles of the apolipoprotein gene. This gene is generally responsible for fat metabolism. Carriers of apolipoprotein ε4 have been found to show significantly higher amyloid retention rates when compared to non-carriers. (Drzezga, A. et al., "Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease." Neurology. 2009; 72: 1487-94.) In some embodiments, the subject is a heterozygous carrier of the apolipoprotein E ε4 gene allele. In some embodiments, the subject is a homozygous carrier of the apolipoprotein E ε4 gene allele.
[0486] As used herein, whether an early AD subject is "amyloid positive" or "amyloid negative" is based on longitudinal PET assessments such as amyloid imaging uptake in the brain; and / or using a PET-based assay such as Aβ 1-42 Whether a patient has a positive amyloid burden, as indicated by CSF assessment of the presence of amyloid pathology (soluble CSF biomarker analysis), will be determined. In some embodiments, qualitative visual reading of PET scans will be used to determine amyloid positive versus amyloid negative by categorizing subjects as having "normal" or "abnormal" uptake based on the PET image pattern. The reader will be trained and calibrated to recognize brain PET images with abnormal or normal uptake patterns, or to detect amyloid via semi-quantitative or quantitative methods.
[0487] As used herein, the term "treat" refers to obtaining beneficial or desired results, including but not limited to, a therapeutic benefit, which means the eradication or amelioration of one or more of the underlying condition being treated or the physiological symptoms associated therewith.
[0488] As used herein, the term "prevent" refers to obtaining a beneficial or desired result, including but not limited to a prophylactic benefit. For a prophylactic benefit, a composition may be administered to a subject at risk for developing Alzheimer's disease; to a subject having one or more preclinical symptoms but not clinical symptoms of Alzheimer's disease; or to a subject reporting one or more of the physiological symptoms of Alzheimer's disease, even though a clinical diagnosis of Alzheimer's disease has not yet been made. As used herein, "prevent" may further include a therapeutic benefit, which means eradication or amelioration of one or more of the underlying condition being treated or the physiological symptoms associated therewith.
[0489] Levels of pre-AD biomarkers that may indicate Alzheimer's disease include, but are not limited to, brain amyloid levels, cerebrospinal fluid Aβ 1-42Levels of total tau, cerebrospinal fluid neurogranin, and cerebrospinal fluid neurociliary light chain. For example, subjects treated with elenbecestat (E2609), a BACE inhibitor, whose baseline PET standardized uptake value ratio (SUVr value) for amyloid protein was 1.4 to 1.9 were found to exhibit the greatest reduction in cognitive decline during treatment. See Lynch, SY et al., "Elenbecestat, a BACE inhibitor: results from a Phase 2 study in subjects with mild cognitive impairment and mild-to-moderate dementia due to Alzheimer's disease," poster P4-389, Alzheimer's Association International Conference, July 22-26, 2018, Chicago, IL, USA. Similarly, it was found that subjects with baseline florbetapir amyloid PET SUVr levels below 1.2 did not exhibit sufficient cognitive decline to be detected, while subjects with SUVr levels above 1.6 were associated with a plateau effect, in which amyloid levels reached a saturating level and treatment did not cause changes in cognitive measures. See Dhadda, S. et al., “Baseline florbetapir amyloid PET standard update value ratio (SUVr) can predict clinical progression in prodromal Alzheimer's disease (pAD).” Poster P4-291, Alzheimer's Association International Conference, July 22–26, 2018, Chicago, IL, USA.
[0490] As used herein, the term "serious adverse event" or "SAE" means an event observed following administration of a composition described herein that: (1) results in death; (2) is life-threatening; (3) requires inpatient hospitalization or prolongs an existing hospitalization; (4) results in permanent or severe disability / incapacity; and / or (5) is a congenital anomaly / birth defect.
[0491] The severity of a serious adverse event can be assessed based on a uniform scale used in the art. For example, the severity of a subject's serious adverse event can be assessed according to the National Cancer Institute's "Common Terminology Criteria for Adverse Events" or "CTCAE." A description of various CTCAE adverse event grades is set forth below:
[0492] -Grade 1: Mild; asymptomatic or mildly symptomatic; clinical or diagnostic observations only; no intervention indicated.
[0493] - Grade 2: Moderate; minor, local, or noninvasive intervention is indicated; age-related limitations in instrumental activities of daily living.
[0494] -Grade 3: Severe or medically significant, but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; incapacitating; limitation of self-care activities of daily living.
[0495] - Grade 4: Life-threatening consequences; urgent intervention indicated.
[0496] -Grade 5: Death related to adverse events.
[0497] As used herein, the term "erenbista" refers to the compound N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-fluoro[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof. erenbista is a β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor (see, for example, U.S. Patent Nos. 8,158,620 and 8,426,584) and is also known as E2609.
[0498]
[0499] At least one anti-Aβ protofibril antibody
[0500] As used herein, at least one anti-Aβ protofibril antibody is selected from monoclonal antibodies (mAbs) that preferentially bind to large soluble amyloid beta (Aβ) oligomers and / or aggregates (also referred to as protofibrils) compared to, for example, Aβ monomers. See, e.g., Figure 61 As used herein, the term "preferentially binds" refers to an antibody that binds to Aβ peptide at least 10-fold, at least 20-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 60-fold, at least 70-fold, at least 80-fold, at least 90-fold, at least 100-fold, at least 125-fold, at least 150-fold, at least 175-fold, at least 200-fold, at least 225-fold, at least 250-fold, at least 275-fold more potently than it binds to other forms of Aβ peptide (e.g., as protofibrils and monomers, respectively). , at least 300-fold, at least 325-fold, at least 350-fold, at least 375-fold, at least 400-fold, at least 425-fold, at least 450-fold, at least 475-fold, at least 500-fold, at least 550-fold, at least 600-fold, at least 650-fold, at least 700-fold, at least 750-fold, at least 800-fold, at least 850-fold, at least 900-fold, at least 950-fold, at least 1000-fold, or at least 1050-fold greater potency in binding to Aβ oligomers and / or protofibrils. The potency of binding to various forms of Aβ can be determined by methods well known in the art, such as ELISA analysis and surface plasmon resonance (SPR).
[0501] In some embodiments, the selectivity of the at least one anti-Aβ protofibril antibody is measured by ELISA analysis. In some embodiments, the preferential binding of the at least one anti-Aβ protofibril antibody is measured by surface plasmon resonance.
[0502] In some embodiments, the preferential binding of BAN2401 is measured by ELISA assay. In some embodiments, the selectivity of BAN2401 is measured by surface plasmon resonance.
[0503] For example, it has been found that BAN2401 binds to Aβ protofibrils with a potency 200 to 1000 times greater than that of Aβ monomers, and BAN2401 binds to Aβ protofibrils with a potency 40 times greater than that of Aβ protofibrils. International Patent Application Publication No. WO 2007 / 108756A1, p. 13 and Figure 2See also Lord, A. et al., “An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease.” 2009;26:425-34; and Swanson, CJ et al., “Pharmacology of BAN2401: A Monoclonal Antibody Selective for Aβ Protofibrils.” Poster P4-286, Alzheimer's Association International Conference, July 13-18, 2013. This potency difference was determined by a sandwich ELISA assay in which BAN2401 was coated onto each well of a plate and different Aβ forms were added to each well at increasing concentrations. Ibid. Measurement of bound Aβ forms was performed by adding biotinylated mAb158 and HRP-labeled streptavidin, and color development was measured according to the manufacturer's protocol. Similarly, BAN2401 was found to have weak affinity for the N-terminal portion of Aβ peptides and Aβ monomers, and no binding to the C-terminal fragment of Aβ was observed. Same as above. Affinity was determined using a competition ELISA assay in which ELISA plates were coated with human Aβ protofibrils, followed by incubation of BAN2401 with increasing amounts of different Aβ forms. Same as above. The incubation mixture was added to the wells of a microtiter plate, and free antibody was allowed to bind to the immobilized protofibrils in the wells. BAN2401 antibody was measured using a secondary antibody. Same as above.
[0504] In some embodiments, at least one anti-Aβ protofibril antibody comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) comprising the amino acid sequence of SEQ ID NO: 5 (HCDR1), SEQ ID NO: 6 (HCDR2), and SEQ ID NO: 7 (HCDR3); and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) comprising the amino acid sequence of SEQ ID NO: 8 (LCDR1), SEQ ID NO: 9 (LCDR2), and SEQ ID NO: 10 (LCDR3).
[0505] The assignment of amino acids to the various domains is generally based on the definitions in SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST (Kabat et al., 5th ed., US Department of Health and Human Services, NIH Publication No. 91-3242, 1991, hereinafter referred to as the "Kabat report").
[0506] In some embodiments, at least one anti-Aβ protofibril antibody comprises a human constant region. In some embodiments, the human constant region of at least one anti-Aβ protofibril antibody comprises a heavy chain constant region selected from IgG1, IgG2, IgG3, IgG4, IgM, IgA, IgE, and any allelic variant thereof as disclosed in the Kabat report. Any one or more of such sequences may be used in the present invention. In some embodiments, the heavy chain constant region is selected from IgG1 and its allelic variants. The amino acid sequence of the human IgG1 constant region is known in the art and is shown in SEQ ID NO: 3.
[0507] In some embodiments, the human constant region of at least one anti-Aβ antibody comprises a light chain constant region selected from the group consisting of κ-λ chain constant regions and any allelic variants thereof as discussed in the Kabat report. Any one or more of these sequences may be used in the present invention. In some embodiments, the light chain constant region is selected from the group consisting of κ and its allelic variants. The amino acid sequence of the human κ chain constant region is known in the art and is shown in SEQ ID NO: 4.
[0508] In some embodiments, at least one anti-Aβ protofibril antibody comprises human heavy and light chain variable region frameworks. In some embodiments, at least one anti-Aβ protofibril antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1; and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. In some embodiments, at least one anti-Aβ protofibril antibody comprises a human IgG1 heavy chain constant region and a human Igκ light chain constant region. In some embodiments, at least one anti-Aβ protofibril antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 3; and a light chain constant region comprising the amino acid sequence of SEQ ID NO: 4.
[0509] In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401. BAN2401 is a humanized IgG1 monoclonal form of mAb158, a murine monoclonal antibody generated to target protofibrils and disclosed in WO 2007 / 108756 and Journal of Alzheimer's Disease 43:575-588 (2015). BAN2401 is at least one anti-Aβ protofibril antibody that exhibits low affinity for Aβ monomers while binding with high selectivity for soluble Aβ aggregate species. For example, BAN2401 has been reported to exhibit selectivity for soluble Aβ protofibrils that is approximately 1000-fold and 5- to 10-fold higher than for Aβ monomers or insoluble Aβ protofibrils, respectively.
[0510] BAN2401 comprises (a) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 1; and (b) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 2. The full sequence of BAN2401 is shown in SEQ ID NO: 11 and SEQ ID NO: 12, and is described in WO 2007 / 108756 and Journal of Alzheimer's Disease 43: 575-588 (2015).
[0511] Other non-limiting examples of antibodies suitable for use as at least one anti-Aβ protofibril antibody in the present invention include antibodies disclosed in WO 2002 / 003911, WO 2005 / 123775, WO 2007 / 108756, WO 2011 / 001366, WO 2011 / 104696, and WO 2016 / 005466.
[0512] A therapeutically effective amount of at least one anti-Aβ protofibril antibody
[0513] The methods of the present invention comprise administering to a subject a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. As used herein, the term "therapeutically effective amount" refers to an amount of a compound or pharmaceutical composition sufficient to produce the desired therapeutic effect.
[0514] One of ordinary skill in the art will understand that the therapeutically effective amount of at least one anti-Aβ protofibril antibody administered to a subject may depend on a variety of factors, including the pharmacodynamic characteristics, route of administration, frequency of treatment, and the health status, age, and weight of the subject to be treated, and with the information disclosed herein, will be able to determine the appropriate amount for each subject.
[0515] In some embodiments, a therapeutically effective amount is a dose selected to improve efficacy and / or maintain efficacy and improve at least one of safety and tolerability. In some embodiments, a therapeutically effective amount is selected to reduce at least one side effect and simultaneously improve efficacy and / or maintain efficacy.
[0516] In some embodiments, the subject is administered 0.5 mg / kg to 45 mg / kg, 0.5 mg / kg to 40 mg / kg, 0.5 mg / kg to 35 mg / kg, 0.5 mg / kg to 30 mg / kg, 0.5 mg / kg to 25 mg / kg, 0.5 mg / kg to 20 mg / kg, 0.5 mg / kg to 15 mg / kg, 0.5 mg / kg to 10 mg / kg, 0.5 mg / kg to 5 mg / kg, or 0.5 mg / kg to 2.5 mg / kg of at least one anti-Aβ protofibril antibody relative to the subject's body weight.
[0517] In some embodiments, the subject is administered 2.5 mg / kg to 45 mg / kg, 2.5 mg / kg to 40 mg / kg, 2.5 mg / kg to 35 mg / kg, 2.5 mg / kg to 30 mg / kg, 2.5 mg / kg to 25 mg / kg, 2.5 mg / kg to 20 mg / kg, 2.5 mg / kg to 15 mg / kg, 2.5 mg / kg to 10 mg / kg, or 2.5 mg / kg to 5 mg / kg of at least one anti-Aβ protofibril antibody, relative to the subject's body weight.
[0518] In some embodiments, the subject is administered 5 mg / kg to 45 mg / kg, 5 mg / kg to 40 mg / kg, 5 mg / kg to 35 mg / kg, 5 mg / kg to 30 mg / kg, 5 mg / kg to 25 mg / kg, 5 mg / kg to 20 mg / kg, 5 mg / kg to 15 mg / kg, or 5 mg / kg to 10 mg / kg of at least one anti-Aβ protofibril antibody relative to the subject's body weight.
[0519] In some embodiments, the subject is administered 7.5 mg / kg to 45 mg / kg, 7.5 mg / kg to 40 mg / kg, 7.5 mg / kg to 35 mg / kg, 7.5 mg / kg to 30 mg / kg, 7.5 mg / kg to 25 mg / kg, 7.5 mg / kg to 20 mg / kg, 7.5 mg / kg to 15 mg / kg, or 7.5 mg / kg to 10 mg / kg of at least one anti-Aβ protofibril antibody, relative to the subject's body weight.
[0520] In some embodiments, the subject is administered at least one anti-Aβ protofibril antibody starting at 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, 20 mg / kg relative to the subject's body weight. In some embodiments, up to 20 mg / kg, 19 mg / kg, 18 mg / kg, 17 mg / kg, 16 mg / kg, 15 mg / kg, 14 mg / kg, 13 mg / kg, 12 mg / kg, 11 mg / kg, 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, or 0.5 mg / kg of at least one anti-Aβ protofibril antibody is administered to the subject relative to the subject's body weight.
[0521] In some embodiments, 0.5 mg / kg of at least one anti-Aβ protofibril antibody is administered to the subject relative to the subject's body weight. In some embodiments, 1 mg / kg of at least one anti-Aβ protofibril antibody is administered to the subject relative to the subject's body weight. In some embodiments, 2 mg / kg of at least one anti-Aβ protofibril antibody is administered to the subject relative to the subject's body weight. In some embodiments, 2.5 mg / kg of at least one anti-Aβ protofibril antibody is administered to the subject relative to the subject's body weight. In some embodiments, 3 mg / kg of at least one anti-Aβ protofibril antibody is administered to the subject relative to the subject's body weight. In some embodiments, 4 mg / kg of at least one anti-Aβ protofibril antibody is administered to the subject relative to the subject's body weight. In some embodiments, 5 mg / kg of at least one anti-Aβ protofibril antibody is administered to the subject relative to the subject's body weight. In some embodiments, 6 mg / kg of at least one anti-Aβ protofibril antibody is administered to the subject relative to the subject's body weight. In some embodiments, 7 mg / kg of at least one anti-Aβ protofibril antibody is administered to the subject relative to the subject's body weight. In some embodiments, 7.5 mg / kg of at least one anti-Aβ protofibril antibody is administered to the subject relative to the subject's body weight. In some embodiments, 8 mg / kg of at least one anti-Aβ protofibril antibody is administered to the subject relative to the subject's body weight. In some embodiments, the subject is administered 9 mg / kg of at least one anti-Aβ protofibril antibody relative to the subject's body weight. In some embodiments, the subject is administered 10 mg / kg of at least one anti-Aβ protofibril antibody relative to the subject's body weight. In some embodiments, the subject is administered 11 mg / kg of at least one anti-Aβ protofibril antibody relative to the subject's body weight. In some embodiments, the subject is administered 12 mg / kg of at least one anti-Aβ protofibril antibody relative to the subject's body weight. In some embodiments, the subject is administered 12.5 mg / kg of at least one anti-Aβ protofibril antibody relative to the subject's body weight. In some embodiments, the subject is administered 13 mg / kg of at least one anti-Aβ protofibril antibody relative to the subject's body weight. In some embodiments, the subject is administered 14 mg / kg of at least one anti-Aβ protofibril antibody relative to the subject's body weight. In some embodiments, the subject is administered 15 mg / kg of at least one anti-Aβ protofibril antibody relative to the subject's body weight. In some embodiments, the subject is administered 16, 17, 18, 19, or 20 mg / kg of at least one anti-Aβ protofibril antibody relative to the subject's body weight. In some embodiments, the subject is administered 21, 22, 23, 24, or 25 mg / kg of at least one anti-Aβ protofibril antibody relative to the subject's body weight.
[0522] In some embodiments, the subject is administered 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 47.5, or 50 mg / kg of at least one anti-Αβ protofibril antibody relative to the subject's body weight.
[0523] As mentioned, in some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401. Thus, in some embodiments, the subject is administered 0.5 mg / kg to 45 mg / kg, 0.5 mg / kg to 40 mg / kg, 0.5 mg / kg to 35 mg / kg, 0.5 mg / kg to 30 mg / kg, 0.5 mg / kg to 25 mg / kg, 0.5 mg / kg to 20 mg / kg, 0.5 mg / kg to 15 mg / kg, 0.5 mg / kg to 10 mg / kg, 0.5 mg / kg to 5 mg / kg, or 0.5 mg / kg to 2.5 mg / kg of BAN2401 relative to the subject's body weight.
[0524] In some embodiments, 2.5 mg / kg to 45 mg / kg, 2.5 mg / kg to 40 mg / kg, 2.5 mg / kg to 35 mg / kg, 2.5 mg / kg to 30 mg / kg, 2.5 mg / kg to 25 mg / kg, 2.5 mg / kg to 20 mg / kg, 2.5 mg / kg to 15 mg / kg, 2.5 mg / kg to 10 mg / kg, or 2.5 mg / kg to 5 mg / kg of BAN2401 is administered to the subject relative to the subject's body weight.
[0525] In some embodiments, 5 mg / kg to 45 mg / kg, 5 mg / kg to 40 mg / kg, 5 mg / kg to 35 mg / kg, 5 mg / kg to 30 mg / kg, 5 mg / kg to 25 mg / kg, 5 mg / kg to 20 mg / kg, 5 mg / kg to 15 mg / kg, or 5 mg / kg to 10 mg / kg of BAN2401 is administered to the subject relative to the subject's body weight.
[0526] In some embodiments, 7.5 mg / kg to 45 mg / kg, 7.5 mg / kg to 40 mg / kg, 7.5 mg / kg to 35 mg / kg, 7.5 mg / kg to 30 mg / kg, 7.5 mg / kg to 25 mg / kg, 7.5 mg / kg to 20 mg / kg, 7.5 mg / kg to 15 mg / kg, or 7.5 mg / kg to 10 mg / kg of BAN2401 is administered to the subject relative to the subject's body weight.
[0527] In some embodiments, BAN2401 is administered to a subject starting at 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, or 20 mg / kg relative to the subject's body weight. In some embodiments, up to 20 mg / kg, 19 mg / kg, 18 mg / kg, 17 mg / kg, 16 mg / kg, 15 mg / kg, 14 mg / kg, 13 mg / kg, 12 mg / kg, 11 mg / kg, 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, or 0.5 mg / kg of BAN2401 is administered to the subject relative to the subject's body weight.
[0528] In some embodiments, 0.5 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 1 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 2 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 2.5 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 3 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 4 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 5 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 6 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 7 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 7.5 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 8 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 9 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 10 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 11 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 12 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 12.5 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 13 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 14 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 15 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 16, 17, 18, 19, or 20 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 21, 22, 23, 24, or 25 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, the subject is administered 27.5 mg / kg, 30 mg / kg, 32.5 mg / kg, 35 mg / kg, 37.5 mg / kg, 40 mg / kg, 42.5 mg / kg, 45 mg / kg, 47.5 mg / kg, or 50 mg / kg of BAN2401 relative to the subject's body weight.
[0529] In some embodiments, 2.5 mg / kg to 10 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 5 mg / kg to 10 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 2.5 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 5 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 7.5 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight. In some embodiments, 10 mg / kg of BAN2401 is administered to a subject relative to the subject's body weight.
[0530] Dosing regimen of at least one anti-Aβ protofibril antibody
[0531] The methods of the present invention comprise administering to a subject a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. Those skilled in the art will appreciate that any of the therapeutically effective amounts of at least one anti-Aβ protofibril antibody disclosed above can be administered one or more times according to one or more dosing regimens. Those skilled in the art will be able to determine the appropriate dosing regimen for each subject based on a variety of factors, including pharmacodynamic profile, route of administration, dosage, and the health, age, and weight of the subject to be treated, with the information disclosed herein.
[0532] In some embodiments, the composition comprising at least one anti-Aβ protofibril antibody is administered daily, every other day, every three days, once a week, once every two weeks ("biweekly"), once every four weeks ("four-week interval"), once a month, once every six weeks, once every eight weeks, once every two months, once every ten weeks, once every twelve weeks, once every three months, once every fourteen weeks, once every sixteen weeks, once every four months, once every eighteen weeks, once every twenty weeks, once every five months, once every 22 weeks, once every 24 weeks, once every six months, once every eight months, once every seven months, once every eight months, once every nine months, once every ten months, once every eleven months, once every twelve months, once every thirteen months, once every thirteen months, once every fourteen months, once every fifteen months, once every sixteen months, once every seventeen months, or once every eighteen months. In some embodiments, the composition comprising at least one anti-Aβ protofibril antibody is administered daily, every other day, every three days, once a week, once every two weeks ("biweekly"), once every four weeks ("four-week interval"), or monthly. In some embodiments, the composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody is administered once every two weeks or once every four weeks. In some embodiments, the composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody is administered once every two weeks. In some embodiments, the composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody is administered once every four weeks.
[0533] In some embodiments, the composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody is administered once a week. In some embodiments, the composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody is administered once every two weeks. In some embodiments, the composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody is administered once every three weeks. In some embodiments, the composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody is administered once every four weeks. In some embodiments, the composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody is administered once a month.
[0534] In some embodiments, the composition comprising a therapeutically effective amount of BAN2401 is administered once a week. In some embodiments, the composition comprising a therapeutically effective amount of BAN2401 is administered once every two weeks. In some embodiments, the composition comprising a therapeutically effective amount of BAN2401 is administered once every three weeks. In some embodiments, the composition comprising a therapeutically effective amount of BAN2401 is administered once every four weeks. In some embodiments, the composition comprising a therapeutically effective amount of BAN2401 is administered once a month.
[0535] In some embodiments, a composition comprising 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, or 10 mg / kg of at least one anti-Aβ protofibril antibody is administered to a subject once weekly, relative to the subject's body weight. In some embodiments, a composition comprising 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, or 10 mg / kg of at least one anti-Aβ protofibril antibody is administered to a subject once every two weeks, relative to the subject's body weight. In some embodiments, a composition comprising 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, or 10 mg / kg of at least one anti-Aβ protofibril antibody is administered to a subject once every three weeks. In some embodiments, a composition comprising 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, or 10 mg / kg of at least one anti-Aβ protofibril antibody is administered to a subject once every four weeks. In some embodiments, a composition comprising 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, or 10 mg / kg of at least one anti-Aβ protofibril antibody is administered to a subject once monthly, relative to the subject's body weight.
[0536] In some embodiments, the subject is administered a composition comprising 10 mg / kg of at least one anti-Aβ protofibril antibody relative to the subject's body weight once every two weeks. In some embodiments, the subject is administered a composition comprising 10 mg / kg of at least one anti-Aβ protofibril antibody relative to the subject's body weight once monthly.
[0537] In some embodiments, a composition comprising 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, or 10 mg / kg of BAN2401, relative to the subject's body weight, is administered to a subject once weekly. In some embodiments, a composition comprising 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, or 10 mg / kg of BAN2401, relative to the subject's body weight, is administered to a subject once every two weeks. In some embodiments, a composition comprising 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, or 10 mg / kg of BAN2401, relative to the subject's body weight, is administered to a subject once every three weeks. In some embodiments, a composition comprising 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, or 10 mg / kg of BAN2401, relative to the subject's body weight, is administered to a subject once every four weeks. In some embodiments, a composition comprising 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, or 10 mg / kg of BAN2401, relative to the subject's body weight, is administered to a subject once monthly.
[0538] In some embodiments, a composition comprising 10 mg / kg BAN2401 relative to the subject's body weight is administered to the subject once every two weeks. In some embodiments, a composition comprising 10 mg / kg BAN2401 relative to the subject's body weight is administered to the subject once monthly.
[0539] Composition comprising at least one anti-Aβ protofibril antibody
[0540] In some embodiments, at least one anti-Aβ protofibril antibody is included in the composition. In some embodiments, the composition consists of at least one anti-Aβ protofibril antibody. In some embodiments, the composition comprises at least one anti-Aβ protofibril antibody and further comprises at least one additional component. The at least one additional component can be selected from suitable physiologically acceptable excipients for human and / or veterinary use.
[0541] The compositions of the present invention may be in the form of tablets, pills, capsules, solutions, and / or any other suitable form deemed suitable by one of ordinary skill in the art. The compositions of the present invention may be administered by any suitable route, including intravenous, subcutaneous, oral, and nasal. In some embodiments, the compositions are formulated as sterile, non-pyrolyzed liquids for intravenous administration. In some embodiments, the compositions are in a physiological saline solution.
[0542] In some embodiments, at least one other component in the composition is selected from a buffer. In some embodiments, at least one other component in the composition is selected from an emulsifier. In some embodiments, at least one other component in the composition is selected from sodium citrate, sodium chloride, and polysorbate 80. In some embodiments, sodium citrate can be present in a concentration ranging from 1mM to 150mM. In some embodiments, sodium citrate can be present in a concentration of 25mM. In some embodiments, sodium chloride can be present in a concentration ranging from 25mM to 250mM. In some embodiments, sodium citrate can be present in a concentration of 125mM. In some embodiments, polysorbate 80 can be present in a concentration ranging from 0.001% (w / v) to 2% (w / v). In some embodiments, polysorbate 80 can be present in a concentration of 0.02% (w / v).
[0543] In some embodiments, the composition is a liquid dosage form comprising at least one anti-Aβ protofibril antibody (such as BAN2401) and further comprising, for example, sodium citrate, sodium chloride, and polysorbate 80. In some embodiments, the composition comprises 10 mg / mL of at least one anti-Aβ protofibril antibody, such as BAN2401, 25 mM sodium citrate, 125 mM sodium chloride, and 0.2% (w / v) polysorbate 80, and has a pH of 5.7.
[0544] therapeutic effects
[0545] Reduction in clinical decline
[0546] Provided herein is a method for reducing clinical decline in a subject with early-stage Alzheimer's disease, the method comprising administering to the subject a composition disclosed herein comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the subject with early-stage Alzheimer's disease has been diagnosed with mild cognitive impairment due to an intermediate likelihood of Alzheimer's disease and / or has been diagnosed with mild Alzheimer's disease dementia. In some embodiments, the subject with early-stage Alzheimer's disease is ApoE4 positive.
[0547] Any of the anti-Aβ protofibril antibodies, their therapeutically acceptable amounts, their dosing regimens, and compositions comprising the same disclosed herein can be used in methods for reducing clinical decline in subjects with early Alzheimer's disease. For example, in some embodiments, a composition comprising 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, or 10 mg / kg of at least one anti-Aβ protofibril antibody, such as BAN2401, is administered to a subject once a week, once every two weeks, once every three weeks, once every four weeks, or once a month, relative to the subject's body weight. In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, or at least 46% relative to placebo as determined by ADCOMS. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0548] In some embodiments, the clinical decline is reduced by 20% to 35% relative to placebo as measured by ADCOMS. In some embodiments, the clinical decline is reduced by 20% to 30% relative to placebo as measured by ADCOMS. In some embodiments, the clinical decline is reduced by 27% to 35% relative to placebo as measured by ADCOMS. In some embodiments, the clinical decline is reduced by at least 20% relative to placebo as measured by ADCOMS. In some embodiments, the clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS. In some embodiments, the clinical decline is reduced by at least 20% relative to placebo as measured by ADCOMS. In some embodiments, the clinical decline is reduced by at least 30% relative to placebo as measured by ADCOMS. In some embodiments, the reduction in clinical decline is measured after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0549] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 45% relative to placebo as measured by ADCOMS. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 30% relative to placebo as measured by ADCOMS. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 46% relative to placebo as measured by ADCOMS. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0550] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, %, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51% or at least 52%, wherein the subject has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0551] In some embodiments, as measured by ADCOMS, clinical decline is reduced by 28% to 33% relative to placebo, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, as measured by ADCOMS, clinical decline is reduced by at least 20% relative to placebo, such as at least 25% or at least 28%, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, as measured by ADCOMS, clinical decline is reduced by at least 25% relative to placebo, such as at least 30% or at least 33%, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, as measured by ADCOMS, clinical decline is reduced by at least 25% relative to placebo, such as at least 30%, at least 35%, at least 40%, at least 45%, at least 50% or at least 52%, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 52% relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is measured 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0552] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease as measured by ADCOMS is reduced by at least 30% relative to placebo. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease as measured by ADCOMS is reduced by at least 25% relative to placebo. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease as measured by ADCOMS is reduced by at least 30% relative to placebo. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease as measured by ADCOMS is reduced by at least 52% relative to placebo. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0553] In some embodiments, the clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, or at least 33% relative to placebo as determined by ADCOMS, wherein the subject has been diagnosed with mild cognitive impairment due to intermediate probability of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0554] In some embodiments, clinical decline is reduced by 28% to 38% relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 20%, such as at least 25%, at least 28%, or at least 33%, relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 25%, such as at least 30% or at least 33%, relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 33%, such as at least 33%, relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0555] In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease as measured by ADCOMS is reduced by at least 33% relative to placebo. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0556] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, %, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77% or at least 78%, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0557] In some embodiments, the clinical decline is reduced by 20% to 80% relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with Alzheimer's dementia. In some embodiments, the clinical decline is reduced by 35% to 78% relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with Alzheimer's dementia. In some embodiments, the clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by at least 50% relative to placebo, such as at least 52% or at least 53%, relative to placebo, as measured by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by at least 70% relative to placebo, such as at least 75% or at least 78%, relative to placebo, as measured by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0558] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of a subject diagnosed with mild Alzheimer's dementia is reduced by at least 70% relative to placebo as measured by ADCOMS. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of a subject diagnosed with mild Alzheimer's dementia is reduced by at least 50% relative to placebo as measured by ADCOMS. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of a subject diagnosed with mild Alzheimer's dementia is reduced by at least 30% relative to placebo as measured by ADCOMS. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of a subject diagnosed with mild Alzheimer's dementia is reduced by at least 52% relative to placebo as measured by ADCOMS. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0559] In some embodiments, the clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, or at least 35% relative to placebo as determined by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0560] In some embodiments, the clinical decline is reduced by 28% to 38% relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by at least 20%, such as at least 25%, at least 28%, or at least 35%, relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by at least 25%, such as at least 30% or at least 35%, relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by at least 35%, relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0561] In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in subjects diagnosed with mild Alzheimer's dementia as measured by ADCOMS is reduced by at least 35% relative to placebo. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0562] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, %, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, or at least 150%. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0563] In some embodiments, clinical decline is reduced by 40% to 150% relative to placebo as measured by ADAS-cog. In some embodiments, clinical decline is reduced by 45% to 145% relative to placebo as measured by ADAS-cog. In some embodiments, clinical decline is reduced by 45% to 55% relative to placebo as measured by ADAS-cog. In some embodiments, clinical decline is reduced by at least 30% relative to placebo as measured by ADAS-cog. In some embodiments, clinical decline is reduced by at least 35% relative to placebo as measured by ADAS-cog. In some embodiments, clinical decline is reduced by at least 40% relative to placebo as measured by ADAS-cog. In some embodiments, clinical decline is reduced by at least 45% relative to placebo as measured by ADAS-cog. In some embodiments, clinical decline is reduced by at least 47% relative to placebo as measured by ADAS-cog. In some embodiments, the reduction in clinical decline described above is measured 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0564] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 100%, such as at least 120% or at least 140%, relative to placebo, as measured by ADAS-cog. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 40%, such as at least 45%, relative to placebo, as measured by ADAS-cog. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 40%, such as at least 45%, relative to placebo, as measured by ADAS-cog. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 47%, relative to placebo, as measured by ADAS-cog. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0565] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 56%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, or at least 58%, wherein the subject has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0566] In some embodiments, clinical decline is reduced by 50% to 70% relative to placebo as measured by ADAS-cog, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 50%, such as at least 52%, at least 55%, or at least 58%, relative to placebo as measured by ADAS-cog, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 58% relative to placebo as measured by ADAS-cog, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0567] In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in subjects diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease as measured by ADAS-cog is reduced by at least 58% relative to placebo. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0568] In some embodiments, the clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, or at least 41% relative to placebo as determined by ADAS-cog, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0569] In some embodiments, clinical decline is reduced by 30% to 50% relative to placebo as measured by ADAS-cog, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, clinical decline is reduced by at least 35%, such as at least 38%, at least 40%, or at least 41%, relative to placebo as measured by ADAS-cog, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, clinical decline is reduced by at least 41% relative to placebo as measured by ADAS-cog, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0570] In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in subjects diagnosed with mild Alzheimer's dementia as measured by ADAS-cog is reduced by at least 41% relative to placebo. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0571] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, or at least 40% relative to placebo as determined by CDR-SB. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0572] In some embodiments, clinical decline is reduced by 20% to 60% relative to placebo as measured by CDR-SB. In some embodiments, clinical decline is reduced by 25% to 60% relative to placebo as measured by CDR-SB. In some embodiments, clinical decline is reduced by 25% to 50% relative to placebo as measured by CDR-SB. In some embodiments, clinical decline is reduced by at least 20% relative to placebo as measured by CDR-SB. In some embodiments, clinical decline is reduced by at least 30% relative to placebo as measured by CDR-SB. In some embodiments, clinical decline is reduced by at least 25%, such as at least 26% or at least 28%, as measured by CDR-SB. In some embodiments, clinical decline is reduced by at least 30%, such as at least 35% or at least 38%, as measured by CDR-SB. In some embodiments, the reduction in clinical decline described above is measured 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0573] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 30%, such as at least 35% or at least 40%, relative to placebo, as determined by CDR-SB. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 30%, such as at least 35% or at least 45%, relative to placebo, as determined by CDR-SB. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 20%, such as at least 25%, relative to placebo, as determined by CDR-SB. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0574] In some embodiments, the clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, or at least 14% relative to placebo as measured by CDR-SB, wherein the subject has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is measured after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0575] In some embodiments, clinical decline is reduced by 10% to 20% relative to placebo as determined by CDR-SB, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 5%, such as at least 10%, at least 12%, or at least 14%, relative to placebo as determined by CDR-SB, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 14% relative to placebo as determined by CDR-SB, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0576] In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in subjects diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease as measured by CDR-SB is reduced by at least 14% relative to placebo. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0577] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least In some embodiments, the reduction in clinical decline is determined to be 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, or at least 51%, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0578] In some embodiments, the clinical decline is reduced by 40% to 60% relative to placebo as determined by CDR-SB, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by at least 45%, such as at least 48%, at least 50%, or at least 51%, relative to placebo as determined by CDR-SB, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by at least 51% relative to placebo as determined by CDR-SB, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0579] In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in subjects diagnosed with mild Alzheimer's dementia as measured by CDR-SB is reduced by at least 51% relative to placebo. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0580] In some embodiments, the reduction in clinical decline is determined 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 30 months, 36 months, 42 months, 48 months, 54 months, 60 months, 63 months, 66 months, and / or 72 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the reduction in clinical decline is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0581] In some embodiments, the reduction in clinical decline is determined 1 month after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the reduction in clinical decline is determined 6 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the reduction in clinical decline is determined 12 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the reduction in clinical decline is determined 18 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the reduction in clinical decline is determined 60 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the reduction in clinical decline is determined 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0582] In some embodiments, the reduction in clinical decline is determined following administration of a composition comprising a therapeutically effective amount of BAN2401.
[0583] In some embodiments, the reduction in clinical decline is determined after 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 30 months, 36 months, 42 months, 48 months, 54 months, 60 months, 63 months, 66 months, and / or 72 months of administration of a composition comprising a therapeutically effective amount of BAN2401. In some embodiments, the reduction in clinical decline is determined after 1 month of administration of a composition comprising a therapeutically effective amount of BAN2401. In some embodiments, the reduction in clinical decline is determined after 6 months of administration of a composition comprising a therapeutically effective amount of BAN2401. In some embodiments, the reduction in clinical decline is determined after 12 months of administration of a composition comprising a therapeutically effective amount of BAN2401. In some embodiments, the reduction in clinical decline is determined after 18 months of administration of a composition comprising a therapeutically effective amount of BAN2401. In some embodiments, the reduction in clinical decline is determined after 60 months of administration of a composition comprising a therapeutically effective amount of BAN2401. In some embodiments, the reduction in clinical decline is determined after 63 months of administration of a composition comprising a therapeutically effective amount of BAN2401.
[0584] In some embodiments, the subject is ApoE4 positive.
[0585] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, At least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, or at least 74%, wherein the subjects are ApoE4 positive. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0586] In some embodiments, as measured by ADCOMS, clinical decline is reduced by 60% to 80%, such as 63% to 74%, relative to placebo, wherein the subject is ApoE4 positive. In some embodiments, as measured by ADCOMS, clinical decline is reduced by at least 60%, such as at least 63%, relative to placebo, wherein the subject is ApoE4 positive. In some embodiments, as measured by ADCOMS, clinical decline is reduced by at least 65%, such as at least 67%, relative to placebo, wherein the subject is ApoE4 positive. In some embodiments, as measured by ADCOMS, clinical decline is reduced by at least 70%, such as at least 74%, relative to placebo, wherein the subject is ApoE4 positive.
[0587] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of ApoE4-positive subjects is reduced by at least 70% relative to placebo as measured by ADCOMS. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of ApoE4-positive subjects is reduced by at least 60% relative to placebo as measured by ADCOMS. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of ApoE4-positive subjects is reduced by at least 50%, such as at least 55% or at least 60%, relative to placebo as measured by ADCOMS. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of ApoE4-positive subjects is reduced by at least 63% relative to placebo as measured by ADCOMS. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0588] In some embodiments, relative to placebo, as measured by ADAS-cogA decrease in clinical decline of at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, %, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, At least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100%, at least 101%, at least 102%, at least 103%, at least 104%, at least 105%, at least 106%, at least 107%, at least 108%, at least 109%, at least 110%, at least 115%, at least 120%, at least 125%, at least 130%, at least 135%, at least 140%, at least 145%, at least 150%, at least 155%, at least 160%, at least 166%, at least 170%, at least 171%, at least 172%, at least 173%, at least 174%, at least 175%, at least 176%, at least 177%, at least 178%, at least 179%, at least 180%, at least 181%, at least 182%, at least 183%, at least 184%, at least 185%, at least 186%, at least 187%, at least 188%, at least 189%, at least 190%, at least 191%, at least 192%, at least 193%, at least 194%, at least 195%, at least 196%, at least In some embodiments, the subject is at least 25%, at least 26%, at least 27%, at least 28%, at least 290%, at least 295%, at least 300%, at least 305%, at least 310%, at least 315%, at least 320%, at least 325%, at least 330%, or at least 331%, wherein the subject is ApoE4 positive. In some embodiments, the subject is at least 25%, at least 26%, at least 27%, at least 28%, at least 290%, at least 295%, at least 300%, at least 305%, at least 310%, at least 315%, at least 320%, at least 325%, at least 330%, or at least 331%, wherein the subject is ApoE4 positive.The reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0589] In some embodiments, as measured by ADAS-cog, clinical decline is reduced by 70% to 400%, such as 80% to 350%, relative to placebo, wherein the subject is ApoE4 positive. In some embodiments, as measured by ADAS-cog, clinical decline is reduced by at least 70%, such as at least 75% or at least 80%, relative to placebo, wherein the subject is ApoE4 positive. In some embodiments, as measured by ADAS-cog, clinical decline is reduced by at least 80%, such as at least 90% or at least 100%, relative to placebo, wherein the subject is ApoE4 positive. In some embodiments, as measured by ADAS-cog, clinical decline is reduced by at least 300%, such as at least 330%, relative to placebo, wherein the subject is ApoE4 positive. In some embodiments, the reduction in clinical decline described above is measured after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0590] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-positive subjects is reduced by at least 300% relative to placebo as measured by ADAS-cog. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-positive subjects is reduced by at least 80%, such as at least 90% or at least 100%, relative to placebo as measured by ADAS-cog. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-positive subjects is reduced by at least 70%, such as at least 75%, at least 80%, or at least 84%, relative to placebo as measured by ADAS-cog. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-positive subjects is reduced by at least 84% relative to placebo as measured by ADAS-cog. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0591] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, At least 3%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, or at least 87%, wherein the subjects are positive for ApoE4. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0592] In some embodiments, as determined by CDR-SB, clinical decline is reduced by 35% to 150%, such as 40% to 100% or 45% to 90%, relative to placebo, wherein the subject is ApoE4 positive. In some embodiments, as determined by CDR-SB, clinical decline is reduced by at least 35%, such as at least 40% or at least 45%, relative to placebo, wherein the subject is ApoE4 positive. In some embodiments, as determined by CDR-SB, clinical decline is reduced by at least 50%, such as at least 55% or at least 60%, relative to placebo, wherein the subject is ApoE4 positive. In some embodiments, as determined by CDR-SB, clinical decline is reduced by at least 70%, such as at least 80% or at least 85%, relative to placebo, wherein the subject is ApoE4 positive. In some embodiments, the reduction in clinical decline described above is measured after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0593] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of ApoE4-positive subjects is reduced by at least 35%, such as at least 40% or at least 45%, relative to placebo, as determined by CDR-SB. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of ApoE4-positive subjects is reduced by at least 70%, such as at least 75% or at least 80%, relative to placebo, as determined by CDR-SB. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of ApoE4-positive subjects is reduced by at least 50%, such as at least 55% or at least 60%, relative to placebo, as determined by CDR-SB. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of ApoE4-positive subjects is reduced by at least 60%, relative to placebo, as determined by CDR-SB. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0594] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, In some embodiments, the reduction in clinical decline is determined at least 2%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, or at least 59%, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined at 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0595] In some embodiments, as determined by ADCOMS, clinical decline is reduced by 30% to 70%, such as 38% to 59%, relative to placebo, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, as determined by ADCOMS, clinical decline is reduced by at least 30%, such as at least 35% or at least 38%, relative to placebo, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, as determined by ADCOMS, clinical decline is reduced by at least 45%, such as at least 50% or at least 53%, relative to placebo, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 50%, such as at least 55% or at least 59%, relative to placebo, as measured by ADCOMS, wherein the subject is ApoE4 positive and wherein the subject has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is measured 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0596] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of ApoE4-positive subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease as measured by ADCOMS is reduced by at least 50%, such as at least 55%, relative to placebo. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of ApoE4-positive subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease as measured by ADCOMS is reduced by at least 30%, such as at least 35%, relative to placebo. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of ApoE4-positive subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease as measured by ADCOMS is reduced by at least 45%, such as at least 50% or at least 55%, relative to placebo. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0597] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, 3%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100%, at least 101%, at least 102%, at least 103%, at least 104%, at least 105 , at least 106%, at least 107%, at least 108%, at least 109%, at least 110%, at least 115%, at least 120%, at least 125%, at least 130%, at least 135%, at least 140%, at least 145%, at least 150%, at least 155%, at least 160%, at least 165%, at least 170%, at least 175%, at least 180%, at least 185%, at least 190%, at least 195%, at least 200%, at least 205%, at least 210%, or at least 211%, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0598] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-positive subjects diagnosed with mild Alzheimer's dementia as measured by ADCOMS is reduced by at least 100%, such as at least 110%, relative to placebo. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-positive subjects diagnosed with mild Alzheimer's dementia as measured by ADCOMS is reduced by at least 100%, such as at least 110%, relative to placebo. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-positive subjects diagnosed with mild Alzheimer's dementia as measured by ADCOMS is reduced by at least 65%, such as at least 70% or at least 75%, relative to placebo. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0599] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, %, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, At least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100%, at least 101%, at least 102%, at least 103%, at least 104%, at least 105%, at least 106%, At least 107%, at least 108%, at least 109%, at least 110%, at least 115%, at least 120%, at least 125%, at least 130%, at least 135%, at least 140%, at least 145%, at least 150%, at least 155%, at least 160%, at least 165%, at least 170%, at least 175%, at least 180%, at least 185%, at least 190%, at least 195%, at least 200%, at least 205%, at least 210%, or at least 211%, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0600] In some embodiments, as determined by ADAS-Cog, clinical decline is reduced by 40% to 300%, such as 45% to 250% or 50% to 250%, relative to placebo, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, as determined by ADAS-Cog, clinical decline is reduced by at least 40%, such as at least 45% or at least 50%, relative to placebo, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, as determined by ADAS-Cog, clinical decline is reduced by at least 60%, such as at least 70%, at least 75%, or at least 80%, relative to placebo, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 100%, such as at least 150% or at least 200%, relative to placebo, as measured by ADAS-Cog, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0601] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-positive subjects diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease as measured by ADAS-cog is reduced by at least 100%, such as at least 150% or at least 200%, relative to placebo. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-positive subjects diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease as measured by ADAS-cog is reduced by at least 40%, such as at least 45% or at least 50%, relative to placebo. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-positive subjects diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease as measured by ADAS-cog is reduced by at least 50%, such as at least 60%, at least 70%, or at least 75%, relative to placebo. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0602] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, In some embodiments, the reduction in clinical decline is determined at least 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0603] In some embodiments, the clinical decline is reduced by 20% to 90%, such as 25% to 80% or 30% to 75%, relative to placebo as determined by CDR-SB, wherein the subject is ApoE4 positive and wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, the clinical decline is reduced by at least 25%, such as at least 30%, relative to placebo as determined by CDR-SB, wherein the subject is ApoE4 positive and wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, the clinical decline is reduced by at least 30%, such as at least 35% or 40%, relative to placebo as determined by CDR-SB, wherein the subject is ApoE4 positive and wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 35%, such as at least 40% or 45%, relative to placebo, as determined by CDR-SB, wherein the subject is ApoE4 positive and wherein the subject has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0604] In some embodiments, a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody reduces clinical decline in ApoE4-positive subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease, as measured by CDR-SB, by at least 35%, such as at least 40% or at least 45%, relative to placebo. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline in ApoE4-positive subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease, as measured by CDR-SB, is reduced by at least 20%, such as at least 25% or at least 30%, relative to placebo. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline in ApoE4-positive subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease, as measured by CDR-SB, is reduced by at least 35%, such as at least 40%, relative to placebo. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0605] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, At least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least In some embodiments, the reduction in clinical decline is determined after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody for 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months.
[0606] In some embodiments, the clinical decline is reduced by 76% to 119% relative to placebo as measured by ADCOMS, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by 76% relative to placebo as measured by ADCOMS, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by 113% relative to placebo as measured by ADCOMS, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by 119% relative to placebo as measured by ADCOMS, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0607] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, At least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least %, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100%, at least 101%, at least 102%, at least 103%, at least 104%, at least 105%, at least 106%, at least 107%, at least 108%, at least 109%, at least 110%, at least 111%, at least 112%, at least 113%, at least 114%, at least 115%, at least 116%, at least 117%, at least %, at least 118%, at least 119%, at least 120%, at least 121%, at least 122%, at least 123%, at least 124%, at least 125%, at least 126%, at least 127%, at least 128%, at least 129%, at least 130%, at least 131%, at least 132%, at least 133%, at least 134%, at least 135%, at least 136%, at least 137%, at least 138%, at least 139%, at least 140%, at least 141%, at least 142%, at least 143%, at least 144%, at least 145%, at least 146%, at least 147%, at least 148%, at least 149%, at least 150%, at least 151%, at least 152%, at least 153%,At least 154%, at least 155%, at least 156%, at least 157%, at least 158%, at least 159%, at least 160%, at least 161%, at least 162%, at least 163%, at least 164%, at least 165%, at least 166%, at least 167%, at least 168%, at least 169%, at least 170%, at least 171%, at least 172%, at least 173%, at least 174%, at least 175%, at least 176%, at least 177%, at least 178%, at least 179%, at least 180%, at least 181%, at least 182%, at least 183%, at least 184%, at least 185%, at least 186%, at least 187%, at least 188%, at least 189%, at least 190%. 75%, at least 176%, at least 177%, at least 178%, at least 179%, at least 180%, at least 190%, at least 200%, at least 210%, at least 220%, at least 230%, at least 240%, at least 250%, at least 275%, at least 300%, at least 325%, at least 350%, at least 375%, at least 400%, at least 425%, at least 450%, at least 475% , at least 500%, at least 550%, at least 600%, at least 650%, at least 700%, at least 750%, at least 800%, at least 850%, at least 900%, at least 950%, at least 1000%, at least 1001%, at least 1002%, at least 1003%, at least 1004%, at least 1005%, at least 1006%, at least 1007%, at least 1008%, at least 1009% , at least 1010%, at least 1011%, at least 1012%, at least 1013%, at least 1014%, at least 1015%, at least 1016%, at least 1017%, at least 1018%, at least 1019%, at least 1020%, at least 1021%, at least 1022%, or at least 1023%, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0608] In some embodiments, clinical decline is reduced by 58% to 1023% relative to placebo as determined by ADAS-Cog, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, clinical decline is reduced by 58% relative to placebo as determined by ADAS-Cog, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, clinical decline is reduced by 171% relative to placebo as determined by ADAS-Cog, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, clinical decline is reduced by 1023% relative to placebo as determined by ADAS-Cog, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0609] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least %, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100%, at least 101%, at least 102%, at least 103%, at least 104%, at least 105%, at least 106%, at least 107%, at least 108%, at least 109%, at least 110%, at least 111%, at least 112%, at least 113%, at least 114%, at least 115%, at least 116%, at least 117%, at least %, at least 118%, at least 119%, at least 120%, at least 121%, at least 122%, at least 123%, at least 124%, at least 125%, at least 126%, at least 127%, at least 128%, at least 129%, at least 130%, at least 131%, at least 132%, at least 133%, at least 134%, at least 135%, at least 136%, at least 137%, at least 138%, at least 139%, at least 140%, at least 141%, at least 142%, at least 143%, at least 144%, at least 145%, at least 146%, at least 147%, at least 148%, at least 149%, at least 150%, at least 151%, at least 152%, at least 153%,At least 154%, at least 155%, at least 156%, at least 157%, at least 158%, at least 159%, at least 160%, at least 161%, at least 162%, at least 163%, at least 164%, at least 165%, at least 166%, at least 167%, at least 168%, at least 169%, at least 170%, at least 171%, at least 172%, at least 173%, or at least 174%, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0610] In some embodiments, as determined by CDR-SB, clinical decline is reduced by 70% to 200%, such as 75% to 180% or 82% to 174%, relative to placebo, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, as determined by CDR-SB, clinical decline is reduced by at least 70%, such as at least 80%, relative to placebo, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, as determined by CDR-SB, clinical decline is reduced by at least 75%, such as at least 80% or at least 85%, relative to placebo, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, as determined by CDR-SB, clinical decline is reduced by at least 150%, such as at least 160% or 170%, relative to placebo, wherein the subject is ApoE4 positive, and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0611] In some embodiments, a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody reduces clinical decline in ApoE4-positive subjects diagnosed with mild Alzheimer's dementia by at least 70%, such as at least 75%, at least 80%, or at least 85%, as measured by CDR-SB, relative to placebo. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline in ApoE4-positive subjects diagnosed with mild Alzheimer's dementia is reduced by at least 130%, such as at least 140%, at least 150%, at least 160%, or at least 170%, relative to placebo. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline in ApoE4-positive subjects diagnosed with mild Alzheimer's dementia is reduced by at least 65%, such as at least 70%, at least 75%, or at least 80%, relative to placebo, as measured by CDR-SB. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0612] In some embodiments, the subject is ApoE4 negative.
[0613] In some embodiments, the clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, or at least 12% relative to placebo as measured by ADCOMS, wherein the subject is ApoE4 negative. In some embodiments, the reduction in clinical decline described above is measured 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0614] In some embodiments, the clinical decline is reduced by 5% to 15% relative to placebo as measured by ADCOMS, wherein the subject is ApoE4 negative. In some embodiments, the clinical decline is reduced by at least 5%, such as at least 7%, relative to placebo as measured by ADCOMS, wherein the subject is ApoE4 negative. In some embodiments, the clinical decline is reduced by at least 10%, such as at least 12%, relative to placebo as measured by ADCOMS, wherein the subject is ApoE4 negative. In some embodiments, the reduction in clinical decline described above is measured after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0615] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-negative subjects is reduced by at least -2% relative to placebo as measured by ADCOMS. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-negative subjects is reduced by at least 10% relative to placebo as measured by ADCOMS. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-negative subjects is reduced by at least 5%, such as at least 7%, relative to placebo as measured by ADCOMS. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-negative subjects is reduced by at least 7% relative to placebo as measured by ADCOMS. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0616] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, relative to placebo, as measured by ADAS-cog. , at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, or at least 72%, wherein the subject is negative for ApoE4. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0617] In some embodiments, as measured by ADAS-cog, clinical decline is reduced by 40% to 80% relative to placebo, wherein the subject is ApoE4 negative. In some embodiments, as measured by ADAS-cog, clinical decline is reduced by at least 35%, such as at least 40% or at least 43%, relative to placebo, wherein the subject is ApoE4 negative. In some embodiments, as measured by ADAS-cog, clinical decline is reduced by at least 40%, such as at least 45% or at least 46%, relative to placebo, wherein the subject is ApoE4 negative. In some embodiments, as measured by ADAS-cog, clinical decline is reduced by at least 65%, such as at least 70% or at least 72%, relative to placebo, wherein the subject is ApoE4 negative. In some embodiments, as measured by ADAS-cog, clinical decline is reduced by at least 43%, relative to placebo, wherein the subject is ApoE4 negative. In some embodiments, the reduction in clinical decline described above is measured after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0618] In some embodiments, the clinical decline is increased by 7%, 6%, 5%, 4%, 3%, 2%, or 1% relative to placebo as determined by CDR-SB, wherein the subject is ApoE4 negative. In some embodiments, the clinical decline is reduced by at least 1%, at least 2%, or at least 3% relative to placebo as determined by CDR-SB, wherein the subject is ApoE4 negative. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0619] In some embodiments, clinical decline is reduced by 3% relative to placebo as determined by CDR-SB, wherein the subject is ApoE4 negative. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the reduction in clinical decline is at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, or at least 26% relative to placebo as measured by ADCOMS, wherein the subject is ApoE4 negative and wherein the subject has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is measured 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0620] In some embodiments, clinical decline is reduced by 15% to 26% relative to placebo as measured by ADCOMS, wherein the subject is ApoE4 negative, and wherein the subject has been diagnosed with mild cognitive impairment due to a moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by 15% relative to placebo as measured by ADCOMS, wherein the subject is ApoE4 negative, and wherein the subject has been diagnosed with mild cognitive impairment due to a moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by 26% relative to placebo as measured by ADCOMS, wherein the subject is ApoE4 negative, and wherein the subject has been diagnosed with mild cognitive impairment due to a moderate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0621] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, At least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least %, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100%, at least 101%, at least 102%, at least 103%, at least 104%, at least 105%, at least 106%, at least 107%, at least 108%, at least 109%, at least 110%, at least 115%, at least 120%, at least 125%, at least 130%, at least 135%, at least 140%, at least 145%, at least 150%, at least 155%, at least 160%, at least 165%, or at least 166%, wherein the subject is ApoE4 negative, and wherein the subject has been diagnosed with mild cognitive impairment due to an intermediate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0622] In some embodiments, as determined by ADAS-Cog, clinical decline is reduced by 50% to 200%, such as 60% to 180% or 65% to 170%, relative to placebo, wherein the subject is ApoE4 negative, and wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, as determined by ADAS-Cog, clinical decline is reduced by 50%, such as at least 55% or at least 65%, relative to placebo, wherein the subject is ApoE4 negative, and wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, as determined by ADAS-Cog, clinical decline is reduced by 70%, such as at least 75% or at least 80%, relative to placebo, wherein the subject is ApoE4 negative, and wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by 150%, such as at least 160%, relative to placebo, as measured by ADAS-Cog, wherein the subject is ApoE4 negative and wherein the subject has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0623] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-negative subjects is reduced by at least 150%, such as at least 160%, as measured by ADAS-Cog, relative to placebo. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-negative subjects is reduced by at least 70%, such as at least 75% or at least 80%, as measured by ADAS-Cog, relative to placebo. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in ApoE4-negative subjects is reduced by at least 50%, such as at least 60% or at least 65%, as measured by ADAS-Cog, relative to placebo. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0624] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, or at least 5% relative to placebo as measured by CDR-SB, wherein the subject is ApoE4 negative, and wherein the subject has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0625] In some embodiments, clinical decline is reduced by at least 5% relative to placebo as measured by CDR-SB, wherein the subject is ApoE4 negative and wherein the subject has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0626] In some embodiments, the reduction in clinical decline is at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12% relative to placebo as measured by CDR-SB, wherein the subject is ApoE4 negative and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is measured after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0627] In some embodiments, the clinical decline is reduced by at least 10%, such as at least 12%, relative to placebo, as determined by CDR-SB, wherein the subject is ApoE4 negative and wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0628] Transition of subjects from amyloid-positive to amyloid-negative
[0629] Also provided herein is a method for converting an amyloid-positive subject into an amyloid-negative subject. In some embodiments, the method comprises administering to the subject a composition comprising at least one anti-Aβ protofibril antibody disclosed herein. In some embodiments, the subject having early Alzheimer's disease has been diagnosed with mild cognitive impairment due to an intermediate likelihood of Alzheimer's disease and / or has been diagnosed with mild Alzheimer's dementia.
[0630] Any of the anti-Aβ protofibril antibodies, therapeutically acceptable amounts thereof, dosing regimens thereof, and compositions comprising the same disclosed herein can be used in methods for converting an amyloid-positive subject into an amyloid-negative subject. For example, in some embodiments, a composition comprising 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, or 10 mg / kg of at least one anti-Aβ protofibril antibody, such as BAN2401, is administered to a subject once a week, once every two weeks, once every three weeks, once every four weeks, or once a month, relative to the subject's body weight.
[0631] In some embodiments, administration of the composition results in at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, %, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, or at least 81% of the subjects converted from amyloid positive to amyloid negative.
[0632] In some embodiments, administration of the composition results in 50% to 100%, such as 60% to 90%, of subjects converting from amyloid positive to amyloid negative, as determined by visual reading of amyloid PET images. In some embodiments, 12 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, administration of the composition results in at least 55%, such as at least 60% or at least 65%, of subjects becoming amyloid negative, as determined by visual reading of amyloid PET images. In some embodiments, 18 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, administration of the composition results in at least 70%, such as at least 75% or at least 80% of subjects becoming amyloid negative, as determined by visual reading of amyloid PET images. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0633] In some embodiments, administration of the composition results in at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 3%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50% , at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, At least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of the subjects are amyloid negative, wherein these subjects are ApoE4 positive.
[0634] In some embodiments, administration of the composition renders 75% to 100%, such as 80% to 100% or 85% to 100%, of the subjects amyloid negative as determined by visual reading of amyloid PET images, wherein these subjects are ApoE4 positive. In some embodiments, administration of the composition renders at least 75%, such as at least 80% or at least 85% of the subjects amyloid negative as determined by visual reading of amyloid PET images, wherein these subjects are ApoE4 positive. In some embodiments, administration of the composition renders 100% of the subjects amyloid negative as determined by visual reading of amyloid PET images, wherein these subjects are ApoE4 positive.
[0635] In some embodiments, 12 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, at least 75%, such as at least 80%, or at least 85%, of ApoE4-positive subjects are amyloid-negative as determined by visual reading of amyloid PET images. In some embodiments, 18 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, at least 75%, such as at least 80%, at least 85%, at least 90%, or at least 95% of ApoE4-positive subjects are amyloid-negative as determined by visual reading of amyloid PET images. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0636] In some embodiments, administration of the composition results in at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least At least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, or at least 79% of the subjects are amyloid negative, wherein these subjects are ApoE4 negative.
[0637] In some embodiments, administration of the composition renders 50% to 100%, such as 55% to 90%, of the subjects amyloid negative as determined by visual reading of amyloid PET images, wherein these subjects are ApoE4 negative. In some embodiments, administration of the composition renders at least 50% of the subjects amyloid negative as determined by visual reading of amyloid PET images, wherein these subjects are ApoE4 negative. In some embodiments, administration of the composition renders at least 70% of the subjects amyloid negative as determined by visual reading of amyloid PET images, wherein these subjects are ApoE4 negative.
[0638] In some embodiments, clinical decline is reduced by 35% to 50% relative to placebo as measured by ADCOMS, wherein the subject is not concurrently taking at least one Alzheimer's disease medication other than BAN2401. In some embodiments, clinical decline is reduced by at least 35%, such as at least 38%, at least 40%, or at least 41%, relative to placebo as measured by ADCOMS, wherein the subject is not concurrently taking at least one Alzheimer's disease medication other than BAN2401. In some embodiments, clinical decline is reduced by at least 41% relative to placebo as measured by ADCOMS, wherein the subject is not concurrently taking at least one Alzheimer's disease medication other than BAN2401. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody other than BAN2401.
[0639] In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in subjects not concurrently taking at least one Alzheimer's disease medication is reduced by at least 41% relative to placebo as measured by ADCOMS. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0640] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, or at least 59%, wherein the subject is not concurrently administered at least one Alzheimer's disease medication. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0641] In some embodiments, clinical decline is reduced by 50% to 70% relative to placebo as measured by ADAS-cog, wherein the subject is not concurrently administered with at least one Alzheimer's disease medication. In some embodiments, clinical decline is reduced by at least 50%, such as at least 55%, at least 57%, or at least 59%, relative to placebo as measured by ADAS-cog, wherein the subject is not concurrently administered with at least one Alzheimer's disease medication. In some embodiments, clinical decline is reduced by at least 59%, relative to placebo, as measured by ADAS-cog, wherein the subject is not concurrently administered with at least one Alzheimer's disease medication. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0642] In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in subjects not concurrently taking at least one Alzheimer's disease medication is reduced by at least 59% relative to placebo as measured by ADAS-cog. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0643] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at %, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, or at least 45%, wherein the subject is not concurrently administered at least one Alzheimer's disease medication. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0644] In some embodiments, clinical decline is reduced by 50% to 70% relative to placebo as measured by ADAS-cog, wherein the subject is not concurrently administered with at least one Alzheimer's disease medication. In some embodiments, clinical decline is reduced by at least 35%, such as at least 40%, at least 42%, or at least 45%, relative to placebo as measured by CDR-SB, wherein the subject is not concurrently administered with at least one Alzheimer's disease medication. In some embodiments, clinical decline is reduced by at least 45% relative to placebo as measured by CDR-SB, wherein the subject is not concurrently administered with at least one Alzheimer's disease medication. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0645] In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in subjects not concurrently taking at least one Alzheimer's disease medication is reduced by at least 45% relative to placebo as measured by CDR-SB. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0646] Concurrent administration of at least one anti-Aβ protofibril antibody and at least one Alzheimer's disease medication other than BAN2401
[0647] In some embodiments, provided herein is a method of reducing clinical decline in a subject with early Alzheimer's disease, the method comprising concurrently administering a therapeutically effective amount of at least one anti-Aβ protofibril antibody and a therapeutically effective amount of at least one Alzheimer's disease medication other than BAN2401. In some embodiments, the clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, or at least 23% relative to placebo as measured by ADCOMS. In some embodiments, the reduction in clinical decline described above is measured after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0648] In some embodiments, the clinical decline is reduced by 15% to 30% relative to placebo as measured by ADCOMS. In some embodiments, the clinical decline is reduced by at least 15%, such as at least 20%, at least 21%, or at least 23%, relative to placebo as measured by ADCOMS. In some embodiments, the clinical decline is reduced by at least 23% relative to placebo as measured by ADCOMS. In some embodiments, the reduction in clinical decline described above is measured 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0649] In some embodiments, after 18 months of administration of a therapeutically effective amount of at least one anti-Aβ protofibril antibody, subjects concomitantly administered a therapeutically effective amount of at least one anti-Aβ protofibril antibody and a therapeutically effective amount of at least one Alzheimer's disease medication other than BAN2401 experience a reduction in clinical decline of at least 23% relative to placebo as measured by ADCOMS. In some embodiments, 10 mg / kg of the at least one anti-Aβ protofibril antibody is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401. In some embodiments, the at least one Alzheimer's disease medication is selected from elenbid, donepezil, galantamine, memantine, and rivastigmine. In some embodiments, the at least one Alzheimer's disease medication is a combination of donepezil and memantine.
[0650] In some embodiments, donepezil can be administered at an approved dose. In some embodiments, galantamine can be administered at an approved dose. In some embodiments, memantine can be administered at an approved dose. In some embodiments, rivastigmine can be administered at an approved dose.
[0651] In some embodiments, Erenbista can be administered at a dose ranging from 5 mg / day to 100 mg / day, 10 mg / day to 75 mg / day, 5 mg / day to 50 mg / day, or 15 mg / day to 50 mg / day. In some embodiments, Erenbista can be administered at a dose ranging from about 5 mg / day to about 100 mg / day, about 10 mg / day to about 75 mg / day, about 5 mg / day to about 50 mg / day, or about 15 mg / day to about 50 mg / day. In some embodiments, Erenbista can be administered at a dose of 5 mg / day, 10 mg / day, 15 mg / day, 20 mg / day, 25 mg / day, 30 mg / day, or 50 mg / day. In some embodiments, Erenbista can be administered at a dose of 5 mg / day. In some embodiments, Erenbista can be administered at a dose of 15 mg / day. In some embodiments, Erenbista can be administered at a dose of 50 mg / day.
[0652] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, or at least 41% relative to placebo as determined by ADCOMS. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0653] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, or at least 39% relative to placebo as measured by ADAS-cog, wherein the subject is concomitantly administered at least one Alzheimer's disease drug other than BAN2401. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0654] In some embodiments, clinical decline is reduced by 30% to 50% relative to placebo as measured by ADAS-cog, wherein the subject is concurrently administered with at least one Alzheimer's disease medication in addition to BAN2401. In some embodiments, clinical decline is reduced by at least 30%, such as at least 35%, at least 37%, or at least 39%, relative to placebo as measured by ADAS-cog, wherein the subject is concurrently administered with at least one Alzheimer's disease medication in addition to BAN2401. In some embodiments, clinical decline is reduced by at least 39%, relative to placebo as measured by ADAS-cog, wherein the subject is concurrently administered with at least one Alzheimer's disease medication in addition to BAN2401. In some embodiments, the reduction in clinical decline described above is measured after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0655] In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in subjects concurrently administered with at least one Alzheimer's disease medication is reduced by at least 39% relative to placebo as measured by ADAS-cog. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401. In some embodiments, the at least one Alzheimer's disease medication is selected from elenbid, donepezil, galantamine, memantine, and rivastigmine. In some embodiments, the at least one Alzheimer's disease medication is a combination of donepezil and memantine.
[0656] In some embodiments, donepezil can be administered at an approved dose. In some embodiments, galantamine can be administered at an approved dose. In some embodiments, memantine can be administered at an approved dose. In some embodiments, rivastigmine can be administered at an approved dose.
[0657] In some embodiments, Erenbista can be administered at a dose ranging from 5 mg / day to 100 mg / day, 10 mg / day to 75 mg / day, 5 mg / day to 50 mg / day, or 15 mg / day to 50 mg / day. In some embodiments, Erenbista can be administered at a dose ranging from about 5 mg / day to about 100 mg / day, about 10 mg / day to about 75 mg / day, about 5 mg / day to about 50 mg / day, or about 15 mg / day to about 50 mg / day. In some embodiments, Erenbista can be administered at a dose of 5 mg / day, 10 mg / day, 15 mg / day, 20 mg / day, 25 mg / day, 30 mg / day, or 50 mg / day. In some embodiments, Erenbista can be administered at a dose of 5 mg / day. In some embodiments, Erenbista can be administered at a dose of 15 mg / day. In some embodiments, Erenbista can be administered at a dose of 50 mg / day.
[0658] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, or at least 20% relative to placebo as measured by CDR-SB, wherein the subject is concurrently administered at least one Alzheimer's disease medication other than BAN2401. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0659] In some embodiments, clinical decline is reduced by 10% to 30% relative to placebo, as determined by CDR-SB, wherein the subject is concurrently administered at least one Alzheimer's disease medication other than BAN2401. In some embodiments, clinical decline is reduced by at least 10%, such as at least 15%, at least 17%, or at least 20%, relative to placebo, as determined by CDR-SB, wherein the subject is concurrently administered at least one Alzheimer's disease medication other than BAN2401. In some embodiments, clinical decline is reduced by at least 20%, relative to placebo, as determined by CDR-SB, wherein the subject is concurrently administered at least one Alzheimer's disease medication other than BAN2401. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0660] In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in subjects concurrently administered with at least one Alzheimer's disease medication is reduced by at least 20% relative to placebo as measured by CDR-SB. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401. In some embodiments, the at least one Alzheimer's disease medication is selected from elenbid, donepezil, galantamine, memantine, and rivastigmine. In some embodiments, the at least one Alzheimer's disease medication is a combination of donepezil and memantine.
[0661] In some embodiments, donepezil can be administered at an approved dose. In some embodiments, galantamine can be administered at an approved dose. In some embodiments, memantine can be administered at an approved dose. In some embodiments, rivastigmine can be administered at an approved dose.
[0662] In some embodiments, Erenbista can be administered at a dose ranging from 5 mg / day to 100 mg / day, 10 mg / day to 75 mg / day, 5 mg / day to 50 mg / day, or 15 mg / day to 50 mg / day. In some embodiments, Erenbista can be administered at a dose ranging from about 5 mg / day to about 100 mg / day, about 10 mg / day to about 75 mg / day, about 5 mg / day to about 50 mg / day, or about 15 mg / day to about 50 mg / day. In some embodiments, Erenbista can be administered at a dose of 5 mg / day, 10 mg / day, 15 mg / day, 20 mg / day, 25 mg / day, 30 mg / day, or 50 mg / day. In some embodiments, Erenbista can be administered at a dose of 5 mg / day. In some embodiments, Erenbista can be administered at a dose of 15 mg / day. In some embodiments, Erenbista can be administered at a dose of 50 mg / day.
[0663] Reduction in brain amyloid levels
[0664] Also provided herein is a method of reducing brain amyloid levels in a subject in need thereof, the method comprising administering a composition disclosed herein comprising a therapeutically effective amount of at least one anti-A[beta] protofibril antibody.
[0665] In some embodiments, the subject has early-stage Alzheimer's disease. In some embodiments, the subject has Alzheimer's disease, Down syndrome, chronic traumatic encephalopathy, cerebral amyloid angiopathy, Lewy body dementia, or another brain disease or condition associated with soluble and / or insoluble Aβ aggregates containing Aβ peptides.
[0666] Those skilled in the art will appreciate that, in addition to subjects with Alzheimer's disease, subjects with other neurodegenerative diseases and conditions also have Aβ plaque deposits in their brains, and thus the methods disclosed herein will be beneficial to subjects with such neurodegenerative diseases and / or conditions. Such diseases and conditions are known to include, for example, Down syndrome, chronic traumatic encephalopathy, cerebral amyloid angiopathy, and Lewy body dementia. (See, e.g., Catafau et al., “Amyloid PET imaging: applications beyond Alzheimer's disease,” Clin. Transl. Imaging 3(1):39-55 (2015); and Banerjee, G. et al., “The increasing impact of cerebral amyloidangiopathy: essential new insights for clinical practice,” J. Neurol. Neurosurg. Psychiatry 88:982-994 (2017).)
[0667] In some embodiments, the subject with early Alzheimer's disease has been diagnosed with mild cognitive impairment due to an intermediate likelihood of Alzheimer's disease and / or has been diagnosed with mild Alzheimer's disease dementia. In some embodiments, the subject with early Alzheimer's disease is ApoE4 positive.
[0668] Any of the anti-Aβ protofibril antibodies, their therapeutically acceptable amounts, their dosing regimens, and compositions comprising the same disclosed herein can be used in methods for reducing brain amyloid levels in subjects with early Alzheimer's disease. For example, in some embodiments, a composition comprising 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, or 10 mg / kg of at least one anti-Aβ protofibril antibody, such as BAN2401, is administered to a subject once a week, once every two weeks, once every three weeks, once every four weeks, or once a month, relative to the subject's body weight.
[0669] In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0670] In some embodiments, the method results in a decrease in brain amyloid levels after administration relative to brain amyloid levels before administration. In some embodiments, brain amyloid levels are reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, 2%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least %, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100%, at least 101%, at least 102%, at least 103%, at least 104%, at least 105%, at least 106%, at least 107%, at least 108%, at least 109%, at least In some embodiments, the reduction in brain amyloid levels is determined by visual reading of amyloid PET images and is expressed as a PET standard uptake value ratio (SUVr value).
[0671] Amyloid positron emission tomography (PET) imaging can be used in the screening phase of a study to confirm the presence of amyloid pathology in the brain of an early AD subject; and / or to assess the effect of at least one anti-AB antibody on amyloid levels in the brain, both using whole-brain analysis (e.g., an average of 5 to 6 cortical regions) and brain regional analysis. In some embodiments, the adjusted mean change from baseline in the PET SUVr value of the subject is reduced by at least -0.10, at least -0.15, at least -0.20, at least -0.25, at least -0.30, at least -0.35, at least -0.40, at least -0.45, at least -0.50, at least -0.55, at least -0.60, at least -0.65, at least -0.70, at least -0.75, at least -0.80, at least -0.85, at least -0.90, or at least -0.95 relative to baseline. In some embodiments, the adjusted mean change from baseline in the PET SUVr value of the subject is reduced by -0.20 to -0.30.
[0672] In some embodiments, the adjusted mean change from baseline in the PET SUVr value of the subject is reduced by at least -0.20, such as at least -0.25, compared to the global cortex mean to the whole cerebellum reference, 12 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the adjusted mean change from baseline in the PET SUVr value of the subject is reduced by at least -0.25, such as at least -0.30, 18 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0673] In some embodiments, the reduction in amyloid in the brain is determined by imaging with a radiotracer that binds to brain Aβ amyloid and is visualized by PET. In some embodiments, the reduction in the corrected mean change from baseline is at least -50, such as at least -55 or at least -59 centiloid units 12 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the reduction in the corrected mean change from baseline is at least -60, such as at least -65 or at least -70 centiloid units 18 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0674] In some embodiments, relative to the cerebrospinal fluid Aβ prior to administration 1-42 This method makes cerebrospinal fluid Aβ 1-42 In some embodiments, the amount of Aβ in the cerebrospinal fluid before administration is reduced. 1-42 This method makes cerebrospinal fluid Aβ 1-42%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100%, at least 101%, at least 102%, at least 103%, at least 104%, at least 105%, at least 106%, at least 107%, at least 108%, at least 109%, 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, At least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
[0675] In some embodiments, administration of the composition results in a reduction in brain amyloid levels of -0.20 to -0.45, such as -0.25 to -0.35, as determined by visual reading of amyloid PET images, where the subject is ApoE4 positive. In some embodiments, administration of the composition results in a reduction in brain amyloid levels of at least -0.25, as determined by visual reading of amyloid PET images, where the subject is ApoE4 positive. In some embodiments, administration of the composition results in a reduction in brain amyloid levels of at least 0.30, as determined by visual reading of amyloid PET images, where the subject is ApoE4 positive.
[0676] In some embodiments, administration of the composition reduces brain amyloid levels by at least -0.01, at least -0.02, at least -0.03, at least -0.04, at least -0.05, at least -0.06, at least -0.07, at least -0.08, at least -0.09, at least -0.10, at least -0.11, at least -0.12, at least -0.13, at least -0.14, at least -0.15, at least -0.16, at least -0.17, at least -0.18, at least -0.19, at least -0.20, at least -0.21, at least -0.22, at least -0.23, at least -0.24, at least -0.25, at least -0.26, at least -0.27, at least -0.28, or at least -0.29 relative to placebo as determined by visual reading of amyloid PET images wherein the subject is ApoE4 negative.
[0677] In some embodiments, administration of the composition results in a reduction in brain amyloid levels of -0.10 to -0.40, as determined by visual reading of amyloid PET images, wherein the subject is ApoE4 negative. In some embodiments, administration of the composition results in a reduction in brain amyloid levels of at least -0.20, as determined by visual reading of amyloid PET images, wherein the subject is ApoE4 negative. In some embodiments, administration of the composition results in a reduction in brain amyloid levels of at least -0.25, as determined by visual reading of amyloid PET images, wherein the subject is ApoE4 negative.
[0678] Biomarker changes
[0679] Cerebrospinal fluid neurogranin levels
[0680] In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein to a subject results in a decrease in cerebrospinal fluid neurogranin levels in the subject. In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein to a subject results in a decrease in cerebrospinal fluid neurogranin levels by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, or at least 10% relative to baseline.
[0681] In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody as disclosed herein to a subject results in a decrease in cerebrospinal fluid neurogranin levels 18 months after administration of the composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody as disclosed herein to a subject results in a decrease in cerebrospinal fluid neurogranin levels by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, or at least 10% relative to baseline 18 months after administration of the composition.
[0682] In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein to a subject results in a decrease in cerebrospinal fluid neurogranin levels by at least about 25 pg / mL, at least about 30 pg / mL, at least about 35 pg / mL, at least about 40 pg / mL, at least about 45 pg / mL, at least about 50 pg / mL, at least about 55 pg / mL, at least about 60 pg / mL, or at least about 65 pg / mL relative to baseline. In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein to a subject results in a decrease in cerebrospinal fluid neurogranin levels by at least about 65 pg / mL relative to baseline.
[0683] In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody as disclosed herein to a subject results in a reduction in cerebrospinal fluid neurogranin levels by at least about 25 pg / mL, at least about 30 pg / mL, at least about 35 pg / mL, at least about 40 pg / mL, at least about 45 pg / mL, at least about 50 pg / mL, at least about 55 pg / mL, at least about 60 pg / mL, or at least about 65 pg / mL relative to baseline 18 months after administration of the composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody as disclosed herein to a subject results in a reduction in cerebrospinal fluid neurogranin levels by at least 65 pg / mL relative to baseline 18 months after administration of the composition.
[0684] In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0685] In some embodiments, the therapeutically effective amount of at least one anti-Aβ protofibril antibody is 10 mg / kg. In some embodiments, a composition disclosed herein comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody is administered biweekly or monthly. In some embodiments, a composition comprising 10 mg / kg of BAN2401 is administered biweekly. In some embodiments, a composition comprising 10 mg / kg of BAN2401 is administered monthly.
[0686] Cerebrospinal fluid neurociliary light chain levels
[0687] In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein to a subject results in a decrease in cerebrospinal fluid neurociliary light chain levels relative to placebo. In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein to a subject results in a decrease in cerebrospinal fluid neurociliary light chain levels by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% relative to placebo.
[0688] In some embodiments, administration of a composition disclosed herein comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody to a subject results in a decrease in cerebrospinal fluid neurociliary light chain levels relative to placebo 18 months after administration of the composition. In some embodiments, administration of a composition disclosed herein comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody to a subject results in a decrease in cerebrospinal fluid neurociliary light chain levels by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% relative to baseline 18 months after administration of the composition.
[0689] In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein to a subject results in a cerebrospinal fluid neurociliary light chain level of greater than about 35 pg / mL, about 40 pg / mL, about 45 pg / mL, about 50 pg / mL, about 55 pg / mL, about 60 pg / mL, about 65 pg / mL, about 70 pg / mL, about 75 pg / mL relative to baseline. In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein to a subject results in a cerebrospinal fluid neurociliary light chain level of no more than about 75 pg / mL relative to baseline.
[0690] In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein to a subject results in a cerebrospinal fluid neurociliary light chain level of greater than about 35 pg / mL, about 40 pg / mL, about 45 pg / mL, about 50 pg / mL, about 55 pg / mL, about 60 pg / mL, about 65 pg / mL, about 70 pg / mL, about 75 pg / mL relative to baseline 18 months after administration of the composition. In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein to a subject results in a cerebrospinal fluid neurociliary light chain level of no more than about 75 pg / mL relative to baseline 18 months after administration of the composition.
[0691] In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0692] In some embodiments, the therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein is 10 mg / kg. In some embodiments, the composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein is administered biweekly or monthly. In some embodiments, the composition comprising 10 mg / kg of BAN2401 is administered biweekly. In some embodiments, the composition comprising 10 mg / kg of BAN2401 is administered monthly.
[0693] Cerebrospinal fluid phosphorylated tau levels
[0694] In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein to a subject results in a decrease in the subject's cerebrospinal fluid phosphorylated tau level. In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein to a subject results in a decrease in cerebrospinal fluid phosphorylated tau level by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, or at least 13% relative to baseline.
[0695] In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody as disclosed herein to a subject results in a decrease in cerebrospinal fluid phosphorylated tau levels 18 months after administration of the composition. In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody as disclosed herein to a subject results in a decrease in cerebrospinal fluid phosphorylated tau levels by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, or at least 13% relative to baseline 18 months after administration of the composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0696] In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein to a subject results in a decrease in cerebrospinal fluid phospho-tau levels relative to baseline by at least about 65 pg / mL, at least about 70 pg / mL, at least about 75 pg / mL, at least about 80 pg / mL, at least about 85 pg / mL, at least about 90 pg / mL, or at least about 95 pg / mL. In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody disclosed herein to a subject results in a decrease in cerebrospinal fluid phospho-tau levels relative to baseline by at least about 95 pg / mL.
[0697] In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody as disclosed herein to a subject results in a reduction in cerebrospinal fluid phospho-tau levels by at least about 65 pg / mL, at least about 70 pg / mL, at least about 75 pg / mL, at least about 80 pg / mL, at least about 85 pg / mL, at least about 90 pg / mL, or at least about 95 pg / mL relative to baseline 18 months after administration of the composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody as disclosed herein to a subject results in a reduction in cerebrospinal fluid phospho-tau levels by at least 95 pg / mL relative to baseline 18 months after administration of the composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0698] In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0699] In some embodiments, the therapeutically effective amount of at least one anti-Aβ protofibril antibody is 10 mg / kg. In some embodiments, a composition disclosed herein comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody is administered biweekly or monthly. In some embodiments, a composition comprising 10 mg / kg of BAN2401 is administered biweekly. In some embodiments, a composition comprising 10 mg / kg of BAN2401 is administered monthly.
[0700] Treatments for Alzheimer's disease
[0701] Reduce clinical decline
[0702] Provided herein is a method of treating a subject with early Alzheimer's disease, the method comprising administering to the subject a composition disclosed herein comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, wherein after 6 months of administration of the composition, the subject's clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS; after 12 months of administration of the composition, the subject's clinical decline is reduced by at least 30% relative to placebo as measured by ADCOMS; and / or after 18 months of administration of the composition, the subject's clinical decline is reduced by at least 25% relative to placebo as measured by ADCOMS. In some embodiments, the subject with early Alzheimer's disease has been diagnosed with mild cognitive impairment due to an intermediate likelihood of Alzheimer's disease and / or has been diagnosed with mild Alzheimer's disease dementia. In some embodiments, the subject with early Alzheimer's disease is ApoE4 positive.
[0703] Any of the anti-Aβ protofibril antibodies, their therapeutically acceptable amounts, their dosing regimens, and compositions comprising the same disclosed herein can be used in methods for reducing clinical decline in subjects with early Alzheimer's disease. For example, in some embodiments, a composition comprising 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, or 10 mg / kg of at least one anti-Aβ protofibril antibody, such as BAN2401, is administered to a subject once a week, once every two weeks, once every three weeks, once every four weeks, or once a month, relative to the subject's body weight. In some embodiments, the clinical decline is reduced by at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, or at least 46% relative to placebo as measured by ADCOMS. In some embodiments, the reduction in clinical decline described above is measured after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0704] In some embodiments, the clinical decline is reduced by 20% to 35% relative to placebo as measured by ADCOMS. In some embodiments, the clinical decline is reduced by 20% to 30% relative to placebo as measured by ADCOMS. In some embodiments, the clinical decline is reduced by 27% to 35% relative to placebo as measured by ADCOMS. In some embodiments, the clinical decline is reduced by at least 20% relative to placebo as measured by ADCOMS. In some embodiments, the clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS. In some embodiments, the clinical decline is reduced by at least 20% relative to placebo as measured by ADCOMS. In some embodiments, the clinical decline is reduced by at least 30% relative to placebo as measured by ADCOMS. In some embodiments, the reduction in clinical decline is measured after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0705] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 45% relative to placebo as measured by ADCOMS. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 30% relative to placebo as measured by ADCOMS. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline is reduced by at least 46% relative to placebo as measured by ADCOMS. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0706] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, %, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51% or at least 52%, wherein the subject has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months and / or 63 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0707] In some embodiments, as measured by ADCOMS, clinical decline is reduced by 28% to 33% relative to placebo, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, as measured by ADCOMS, clinical decline is reduced by at least 20% relative to placebo, such as at least 25% or at least 28%, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, as measured by ADCOMS, clinical decline is reduced by at least 25% relative to placebo, such as at least 30% or at least 33%, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, as measured by ADCOMS, clinical decline is reduced by at least 25% relative to placebo, such as at least 30%, at least 35%, at least 40%, at least 45%, at least 50% or at least 52%, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 52% relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is measured 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0708] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease as measured by ADCOMS is reduced by at least 30% relative to placebo. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease as measured by ADCOMS is reduced by at least 25% relative to placebo. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease as measured by ADCOMS is reduced by at least 30% relative to placebo. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease as measured by ADCOMS is reduced by at least 52% relative to placebo. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0709] In some embodiments, the clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, or at least 33% relative to placebo as determined by ADCOMS, wherein the subject has been diagnosed with mild cognitive impairment due to intermediate probability of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0710] In some embodiments, clinical decline is reduced by 28% to 38% relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 20%, such as at least 25%, at least 28%, or at least 33%, relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 25%, such as at least 30% or at least 33%, relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, clinical decline is reduced by at least 33%, such as at least 33%, relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0711] In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, clinical decline in subjects diagnosed with mild cognitive impairment due to moderate likelihood of Alzheimer's disease as measured by ADCOMS is reduced by at least 33% relative to placebo. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0712] In some embodiments, clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, %, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77% or at least 78%, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0713] In some embodiments, the clinical decline is reduced by 20% to 80% relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with Alzheimer's dementia. In some embodiments, the clinical decline is reduced by 35% to 78% relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with Alzheimer's dementia. In some embodiments, the clinical decline is reduced by at least 35% relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by at least 50% relative to placebo, such as at least 52% or at least 53%, relative to placebo, as measured by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by at least 70% relative to placebo, such as at least 75% or at least 78%, relative to placebo, as measured by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0714] In some embodiments, after 6 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of a subject diagnosed with mild Alzheimer's dementia is reduced by at least 70% relative to placebo as measured by ADCOMS. In some embodiments, after 12 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of a subject diagnosed with mild Alzheimer's dementia is reduced by at least 50% relative to placebo as measured by ADCOMS. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of a subject diagnosed with mild Alzheimer's dementia is reduced by at least 30% relative to placebo as measured by ADCOMS. In some embodiments, after 18 months of administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody, the clinical decline of a subject diagnosed with mild Alzheimer's dementia is reduced by at least 52% relative to placebo as measured by ADCOMS. In some embodiments, the composition comprises 10 mg / kg of at least one anti-Aβ protofibril antibody and is administered biweekly or monthly. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
[0715] In some embodiments, the clinical decline is reduced by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, or at least 35% relative to placebo as determined by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months after administration of a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
[0716] In some embodiments, the clinical decline is reduced by 28% to 38% relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by at least 20%, such as at least 25%, at least 28%, or at least 35%, relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by at least 25%, such as at least 30% or at least 35%, relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the clinical decline is reduced by at least 35%, relative to placebo as measured by ADCOMS, wherein the subject has been diagnosed with mild Alzheimer's dementia. In some embodiments, the reduction in clinical decline described above is determined after 1 month, 6 months, 12 months, 18 months, 60 months, and / or 63 months of administering a composition comprising a ther...
Claims
1. A method of reducing clinical decline in a subject with early-stage Alzheimer's disease, the method comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody.
2. The method of claim 1, wherein the at least one anti-Aβ protofibril antibody comprises three heavy chain complementary determining regions (HCDR1, HCDR2 and HCDR3) comprising the amino acid sequences of SEQ ID NO: 5 (HCDR1), SEQ ID NO: 6 (HCDR2) and SEQ ID NO: 7 (HCDR 3); and three light chain complementary determining regions (LCDR1, LCDR2 and LCDR3) comprising the amino acid sequences of SEQ ID NO: 8 (LCDR1), SEQ ID NO: 9 (LCDR2) and SEQ ID NO: 10 (LCDR3).
3. The method of claim 1, wherein the subject with early Alzheimer's disease has been diagnosed with mild cognitive impairment due to intermediate likelihood of Alzheimer's disease, and / or has been diagnosed with mild Alzheimer's disease dementia.
4. The method according to any one of claims 1 to 3, wherein the subject is ApoE4 positive.
5. The method according to any one of claims 1 to 4, wherein the at least one anti-Aβ protofibril antibody is BAN2401.
6. The method of claim 5, wherein the composition comprises 5 mg / kg to 10 mg / kg BAN2401 relative to the subject's body weight.
7. The method of claim 5, wherein the composition comprises 10 mg / kg BAN2401 relative to the subject's body weight.
8. The method according to any one of claims 1 to 7, wherein the composition is administered once every 2 weeks or once a month.
9. The method according to any one of claims 1 to 8, wherein after 6 months of administration of the composition, the clinical decline is reduced by at least 45% relative to placebo as determined by ADCOMS.
10. The method according to any one of claims 1 to 9, wherein after 12 months of administration of the composition, the clinical decline is reduced by at least 35% relative to placebo as determined by ADCOMS.
